All conditions

Endometrial Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2615
Trials on record
425
Recruiting now
9
Australian sites
35
Phase 3 trials
1
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Endometrial Cancer →

Get alerts when Endometrial Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Endometrial Cancer

Endometrial cancer is a type of cancer that begins in the lining of the uterus (womb), which is called the endometrium. The uterus is part of the female reproductive system, and its lining normally thickens and sheds each month during the menstrual cycle. When cells in this lining grow in an abnormal, uncontrolled way, they can form a cancer. The most common warning sign is unusual vaginal bleeding, particularly bleeding after menopause, which is why this cancer is often detected at an early stage. It is a different condition from ovarian cancer or cervical cancer, though all three affect the female reproductive system.

Endometrial cancer is the most common gynaecological cancer in Australia. Each year, around 3,000 Australian women are diagnosed with it, and it most commonly affects women who are post-menopausal, typically between the ages of 55 and 74. However, it can occur in younger women too. Certain factors can increase a person's risk, including obesity, having never been pregnant, late menopause, or a family history of certain inherited conditions such as Lynch syndrome.

Treatment depends on a number of factors, including how early the cancer was found and how it looks under a microscope. For most people, surgery to remove the uterus (called a hysterectomy) is the main form of treatment, and the ovaries and fallopian tubes are often removed at the same time. Depending on individual circumstances, additional treatments such as radiation therapy, chemotherapy, or hormone therapy may also be used. A specialist medical team, which may include a gynaecological oncologist, radiation oncologist, and other health professionals, will work together to discuss the options that may be suitable for each individual.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Endometrial Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Endometrial Cancer

1 medicine listed on the PBS for Endometrial Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 1 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Medroxyprogesterone Provera Endometrial cancer AU$67.83 Restricted benefit

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Endometrial Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Endometrial Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Endometrial Cancer by country. Australia is highlighted.

Showing the top 10 of 70 countries with trial sites.

Clinical trials for Endometrial Cancer

Showing 426 of 426 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT03517449 · Eisai Inc. Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 1 March 2022
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇴 CO🇫🇷 FR🇩🇪 DE🇮🇪 IE +13 more

Who might be able to join this trial: - People who have been diagnosed with endometrial carcinoma (a type of uterine cancer) confirmed by a laboratory test on a tissue sample. - People whose endometrial cancer has spread, come back, or reached an advanced stage. - People whose cancer has continued to grow after receivi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04073706 · Queensland Centre for Gynaecological Cancer Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2031
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇴 CO🇮🇹 IT🇸🇬 SG🇺🇸 US

**Who might be able to join this trial:** - Women over 18 years old who have been diagnosed with a confirmed cancer of the uterine lining (endometrium) or a related type of uterine cancer called carcinosarcoma, of any cell type. - People whose cancer appears to be confined to the body of the uterus (Stage I disease)....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05640999 · Canadian Cancer Trials Group Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇳🇴 NO🇺🇸 US

**Who might be able to join this trial:** - People who have had surgery to remove the uterus and both ovaries (with or without lymph node removal), with no visible cancer remaining after surgery. - People diagnosed with uterine (endometrial) cancer at Stage I, II, or III, confirmed by a laboratory test on tissue remov...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06153667 · Merit Medical Systems, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇦🇺 AU🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - Women aged 18 or older at the time of joining the trial. - People who have uterine fibroids causing symptoms, where a procedure called embolization (blocking blood flow to the fibroids) is considered appropriate. - People who have given written consent to participate. Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06278857 · Queensland Centre for Gynaecological Cancer Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who are female and at least 18 years old at the time of signing the consent form - People who have been diagnosed with a specific type of early-stage uterine cancer (Stage 1, low-to-moderate grade endometrioid endometrial adenocarcinoma) that has a particular genetic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06340568 · BioNTech SE Phase 3 · 25 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK +17 more

**Who might be able to join this trial:** - Women aged 18 or older (or the minimum age allowed by local rules) who are willing to give informed consent to participate. - People with a confirmed diagnosis of endometrial cancer that has come back (recurred), based on tissue testing. - People whose cancer has a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06432478 · Royal North Shore Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇦🇺 AU

Who might be able to join this trial: - People who are able to give their informed consent to participate in the study - People who have been recommended to receive a type of internal radiation treatment called intracavitary brachytherapy - People whose cancer has been staged between FIGO Stage I and Stage IVA (confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07044336 · AstraZeneca Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 15 October 2027
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ +20 more

**Who might be able to join this trial:** - You have been diagnosed with endometrial carcinoma (uterine cancer) or carcinosarcoma, confirmed by a lab test on a tissue sample. - Your cancer has come back or spread to other parts of the body, with evidence shown on scans or other objective tests. - You have previously re...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07166094 · Genmab Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2029
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇮 FI🇫🇷 FR🇩🇪 DE🇯🇵 JP +7 more

Who might be able to join this trial: - People who have been diagnosed with endometrial cancer (any type except neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) that has come back or continued to grow, confirmed by laboratory testing of tissue or cells. - People who have received at least 1 but no more th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07286331 · GlaxoSmithKline Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 29 February 2028
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇯🇵 JP Panama

**Who might be able to join this trial:** - People who are at least 18 years old and meet the legal age of consent in the country where the trial is taking place. - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus), confirmed by a laboratory test on a tissue sample — including...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00900575 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇺🇸 US

Who might be able to join this trial: - People who are undergoing a colposcopy procedure to help diagnose cervical cancer - People who are having a LEEP procedure (a procedure that removes abnormal tissue from the cervix) to treat early-stage cervical cancer - People who are attending follow-up Pap smear appointments a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02543710 · Haukeland University Hospital Phase 4 · 3 countries Recruiting
Recruiting Phase 4 Est. completion 1 December 2020
🇳🇱 NL🇳🇴 NO🇵🇱 PL

**Who might be able to join this trial:** *Part 1 (Observational stage):* - People who have been referred to a participating research centre because endometrial cancer is suspected or has been confirmed. *Part 2 (Treatment stage):* - People who have endometrial cancer or a type of ovarian cancer (called epithelial ov...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02829437 · Italian Sarcoma Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with a type of uterine cancer called Endometrial Stromal Tumor (EST), based on the World Health Organization's 2003 or 2014 classification guidelines. - You are willing and able to sign a consent form agreeing to take part in the trial. Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02869490 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

"Who might be able to join this trial: - People who have been diagnosed with cervical cancer Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site) Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02993900 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer that has been confirmed through a tissue or cell sample test. - You have cancer of the cervix, uterus, vagina, vulva, or urethra at a stage or situation where internal radiation implant treatment is appropriate (confirm with trial site for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03061435 · Dr. Danielle Vicus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇨🇦 CA

Who might be able to join this trial: - Women aged 40 or older - Women who have previously been diagnosed with a high-grade vulvar skin condition (VIN 2/3) or vulvar cancer Who may not be able to join: - Women who have previously been diagnosed with any type of cancer, except for basal cell skin cancer, cervical cance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03249519 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2094
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with cervical cancer confirmed by tissue testing (biopsy or similar). - People whose cancer is at FIGO Stage IIB to IVA, or at an earlier stage if surgery is not possible or if the patient prefers not to have surgery. - People whose cancer has not s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03362619 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent before any study procedures begin - People older than 10 years of age - People with a good general health and activity level, rated 0 or 1 on a standard oncology performance scale (confirm with trial site) - People expected to survive at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03366051 · AC Camargo Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 December 2024
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with a high-grade form of uterine cancer (specifically grade 3 endometrioid, serous, clear cell, or carcinosarcoma types) - You have a lower-grade endometrioid cancer (grade 1 or 2) that has spread more than halfway through the muscle wall of the uteru...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03400826 · Johns Hopkins University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are female and between 18 and 55 years old at the time of signing consent. - People with a body mass index (a measure of body weight relative to height) below 45. - People who have been diagnosed with uterine fibroids (non-cancerous growths in the uterus) confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03422198 · University of Utah Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a confirmed type of uterine (endometrial) cancer — including endometrioid, serous, clear cell, carcinosarcoma, or other sarcomas — where the cancer started mainly in the uterus, and where a specific internal radiation treatment called vagi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03438474 · Philipps University Marburg Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 15 February 2028
🇩🇪 DE🇯🇵 JP🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with uterine (endometrial) cancer that has been confirmed by a tissue sample, and your cancer is at a specific stage or type as determined by your doctor (confirm with trial site for your exact stage and type) - You have either not yet had surgery for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03463252 · West China Second University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** **If you have endometrial cancer:** - You are 40 years old or younger - You have a strong wish to preserve your fertility (ability to have children in the future) - Your cancer has been confirmed by specialist pathologists as a slow-growing, early-stage type (grade 1 endometri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03534713 · University Hospital, Toulouse Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are a woman diagnosed with cervical cancer that has been confirmed by a tissue biopsy and has spread to lymph nodes near the large blood vessel in the abdomen (called para-aortic lymph nodes), confirmed by a special scan or surgical biopsy - Your cancer is at a stage bet...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03617133 · Medical University of Vienna Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2021
🇦🇹 AT

**Who might be able to join this trial:** - You have cervical cancer that doctors believe can be treated with the goal of a cure, using radiation therapy (with or without chemotherapy) and a type of internal radiation called brachytherapy (BT) - A biopsy has confirmed your cervical cancer is one of these types: squamo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03621904 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 October 2026
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with advanced (FIGO stage III or IV) or recurrent endometrial cancer - People with any type of endometrial carcinoma (all tissue types are considered) - People whose treatment plan includes any form of hormonal therapy - People who have had a tissue...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03624244 · Centre Leon Berard Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have been confirmed by tissue biopsy or pathology testing to have a type of uterine cancer called low grade endometrial stromal sarcoma (ESS) - People whose cancer had spread beyond the uterus at the time of diagnosis, or whose tumour was...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03624712 · University Hospital Tuebingen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with a confirmed uterine cancer, including cervical cancer, endometrial cancer, or sarcoma - If the cancer can be operated on, people who are planned to have surgery (either keyhole/robotic surgery or open surgery) as the main treatment - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03675893 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by lab testing (through cell or tissue samples) to have endometrial cancer that has come back, spread to other parts of the body, or has stopped responding to standard treatments — or for which no standard treatment exists. - People in certain...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03719547 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cervical cancer (adenocarcinoma, squamous cell carcinoma, or adeno-squamous carcinoma), confirmed by a tissue sample test - Your cancer has been classified as an early stage (FIGO stage IB — but not IB3 — or stage IIA1) accordi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03785288 · Kara Romano, MD Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 January 2027
🇺🇸 US

**Who might be able to join this trial:** - The person must be willing and able to sign a consent form and follow the study plan, as assessed by the study doctor. - The person must have had a full hysterectomy and removal of both ovaries and fallopian tubes (either open surgery or keyhole surgery), with or without rem...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03832361 · Alessandro Santin Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have endometrial cancer that has come back or not gone away, confirmed by a CT scan and/or MRI. - People whose cancer is one of these specific types (confirmed by biopsy or pathology report): uterine serous carcinoma (pure or mixed), Grade 2 or Grade 3 endometrial...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03853915 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with a specific type of cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), confirmed by a tissue test, at a certain stage of the disease (FIGO stage IB to IVA). - You are planned to receive a full course of radiation the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03913117 · University of Alabama at Birmingham Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have had mildly abnormal cervical cell results (called ASC-US or LSIL) that have been present for more than 6 months, confirmed by a specific type of cervical smear test - People whose cervical samples have tested positive for a specific strain of HPV called HPV16...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03997110 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇮🇳 IN

**Who might be able to join this trial:** - People with advanced cervical cancer (Stage 3B to 4A) that has been assessed by doctors as not suitable for a full course of curative radiotherapy or chemotherapy-with-radiation, for one of these specific reasons: - The tumour is very large and has spread deeply into the p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04008563 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇨🇦 CA

**Who might be able to join this trial:** - Your Body Mass Index (BMI) is 35 or higher (a measure of body weight relative to height) - You have been diagnosed with either early-stage (Grade 1) uterine cancer of a specific type (endometrioid endometrial cancer) or a pre-cancerous condition of the uterine lining called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04016389 · University Health Network, Toronto Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: **Part 1 – Chemotherapy phase:** - People who have been diagnosed with a specific type of invasive cervical cancer (adenocarcinoma, adenosquamous, or squamous cell type) where the tumour measures more than 2 cm but no larger than 4 cm, confirmed by MRI scan. - People who are preme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04057924 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a moderate cervical cell abnormality (called CIN2), confirmed by a tissue sample (biopsy) - You are between 18 and 39 years old - Your cervical examination (colposcopy) gave a clear enough view to identify the affected area - You are covered by a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04061967 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇸🇪 SE

Who might be able to join this trial: - Women who live in Region Skåne (Sweden) and have had glandular cell changes detected but have not had any follow-up care for those changes - Women who live in Region Skåne, are older than 65 years, and have had cell changes that were not followed up, or have not taken part in cer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04093388 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - Women aged 21 to 65 years old who are due for routine cervical cancer screening as recommended by national health guidelines. Who may not be able to join: - Women who have previously had cervical cancer or an abnormal Pap smear result. - Women who have had a total hysterectomy,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04107181 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇺🇸 US

Who might be able to join this trial: - You are a woman in good general health - You are between 21 and 65 years old - You have had a pelvic exam at some point in the past - You are able to hold a conversation in English - Information about your highest level of education will be collected (confirm with trial site) Wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04131413 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with high-grade cervical cell changes (called CIN2 or CIN3), confirmed by a specialist examination and tissue sample. - People whose cervical cell sample has tested positive for a specific strain of HPV called HPV16 (having other HPV types at t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04212910 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with primary endometrial cancer (cancer of the lining of the uterus), confirmed through a tissue or biopsy test - People aged 18 years or older - People who are considered medically suitable for surgery, with no reasons preventing it and who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04226313 · The Institute of Molecular and Translational Medicine, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇿 CZ

Who might be able to join this trial: - Women between the ages of 30 and 65 years old (for one arm of the trial, women older than 65 are also allowed) - Women who currently live in the Czech Republic - Women who have not taken part in a cervical cancer screening program in the Czech Republic for at least 3 years (appli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04258449 · McGill University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who are at least 18 years old - People who are able to understand what the study involves - People who are able to give their informed consent to participate - People who have a suspected or confirmed cancer of the upper reproductive tract (such as the uterus, ovaries,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04300556 · Eisai Inc. Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 8 August 2030
🇫🇷 FR🇯🇵 JP🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People diagnosed with one of the following cancer types: triple-negative breast cancer (TNBC) that has spread to other parts of the body; a type of lung cancer called non-small cell lung cancer (NSCLC) adenocarcinoma that has spread and has not res...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04362046 · Vancouver Coastal Health Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇦 CA

**Who might be able to join this trial:** - People who are under 40 years of age - People who have received a confirmed tissue biopsy diagnosis of either: (a) early-stage (Grade 1) uterine cancer affecting less than one-third of the uterine lining, or (b) atypical endometrial hyperplasia (an abnormal but non-cancerous...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04403867 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with early-stage uterine (endometrial) cancer and are scheduled to have a procedure to check nearby lymph nodes for cancer spread (called a sentinel lymph node procedure). - People who have been diagnosed with early-stage cervical cancer and are sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04409860 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2024
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with cervical cancer at stage IIb to IVa, where the cancer type is squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma - People who have completed a full course of combined chemotherapy and radiation therapy (chemoradiation), using speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04422366 · Shanghai Bovax Biotechnology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 September 2027
🇨🇳 CN

Who might be able to join this trial: - Chinese women aged 20 to 45 years old who can provide legal identification and have a history of sexual activity - People who fully understand what the study involves, including the risks and benefits, and are willing to sign a consent form - People who are able to read, understa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04453904 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are receiving primary (first-time) treatment for their condition - People who have had a full staging surgery, including removal of the uterus, both ovaries, and fallopian tubes, along with surgical staging - People whose post-surgery tissue samples confirmed a dia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04475354 · Comprehensive Cancer Centre The Netherlands Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2024
🇳🇱 NL

Who might be able to join this trial: **As a patient:** - People who have recently been diagnosed with cervical cancer at stage I, II, or III - People who are 18 years of age or older **As a partner:** - People who are the partner of a patient taking part in this study - People who are 18 years of age or older Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04486352 · Alliance Foundation Trials, LLC. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have endometrial cancer (cancer of the lining of the uterus) that has come back or not gone away, and has gotten worse after at least 1 but no more than 2 previous treatment regimens (hormone therapies like tamoxifen or aromatase inhibitors do not count toward thi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04504006 · Dr. Paul Buderath Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with uterine cancer (endometrial carcinoma), confirmed by a tissue test, at stages I to III - Your cancer is either the common type (endometrioid) or a less common type (non-endometrioid) of uterine cancer - You are well enough to have surgery, with a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04555226 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇨🇳 CN

**Who might be able to join this trial:** - People whose cervical cancer has been confirmed by a pathology test to be one of these types: squamous cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma - People diagnosed with stage IIICr cervical cancer, confirmed by a CT, MRI, or PET/CT scan, where at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04588402 · International Agency for Research on Cancer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇮🇳 IN

Who might be able to join this trial: - Women between 18 and 22 years old who live in Sikkim and are married - Women who are pregnant (pregnancy does not prevent joining this trial) - Sample collection should not take place while a woman is actively menstruating Who may not be able to join: - Women who do not provide...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04661072 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - People who are female - People who are 13 years of age or older - People who have received care at Yale New Haven Hospital, Bridgeport Hospital, Greenwich Hospital, or Lawrence + Memorial Hospital - People who have been diagnosed with any form of CUA (calciphylaxis, a condition a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04683653 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with primary cervical cancer or uterine cancer of any type - People who are 18 years of age or older - People whose cancer has not spread to distant parts of the body, based on international gynaecological cancer staging guidelines - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04712851 · Jonsson Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - Women aged 21 or older who have an active (not yet surgically removed), laboratory-confirmed diagnosis of cervical cell changes classified as CIN grade 2 or 3, or carcinoma in situ (without invasion into surrounding tissue), including cases where the affected areas appear in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04716686 · Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Women aged 18 or older - People who have been confirmed by tissue testing to have serous endometrial cancer or another type of endometrial cancer - People whose cancer is classified as stage III or IV - For **Cohort 1 (maintenance therapy with niraparib alone):** People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04723095 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2044
🇺🇸 US

Who might be able to join this trial: - People who have a personal history of cervical cancer that includes a neuroendocrine component, including mixed tumours, specifically of the small cell, large cell, or undifferentiated high-grade type. - People at any stage — whether currently in treatment, being monitored after...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04733820 · Huazhong University of Science and Technology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with cervical cancer at a specific stage (stage IB3 to IIB, based on 2018 guidelines) and your tumor was larger than 4cm before any treatment began. - Your cervical cancer has been confirmed by a lab test (biopsy), and it is one of these types: squamo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04774419 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a scale used by doctors to measure this — confirm with trial site) - People diagnosed with endometrial cancer of any tissue type (a patho...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04783805 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇪🇸 ES

Who might be able to join this trial: - People of reproductive age who want to have children in the future - People who are willing to be managed without immediate surgical treatment (conservative approach) - People who are committed to attending all scheduled follow-up appointments - People whose colposcopy (a close-u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04831437 · Tehran University of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2023
Iran

**Who might be able to join this trial:** - People diagnosed with a specific type of cervical cancer — either squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma — at certain stages of the disease (FIGO stages IB, IIA, IIB, IIIA, IIIB, or certain IIIC1 cases) - People with stage IIIB disease where kidne...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04831580 · GOG Foundation Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cervical cancer confirmed by a tissue biopsy — either adenocarcinoma (usual/classic/NOS), squamous cell carcinoma, or adenosquamous carcinoma (including glassy cell). - People whose cancer is at a specific early stage (F...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04839614 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - Adult women aged 18 or older. - People with a body mass index (BMI) between 35 and 39.99, plus at least one serious weight-related health condition — such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, liver disease, acid reflux, asthma, severe urinary le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04845828 · Asan Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇰🇷 KR

**Who might be able to join this trial:** - Women between 20 and 80 years old - People who have been diagnosed with uterine (endometrial) cancer confirmed by a tissue sample, and have not yet received any treatment for it - People whose cancer is one of several specific types, including endometrioid, mucinous, serous,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04857528 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with stage I-III anal cancer or stage I-IVA cervical cancer that has tested positive for a protein called p16 (based on a lab test). - You are 18 years of age or older. - Your doctors are planning to use radiation therapy as your main treatment, with or wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04859530 · Prof. Patrick Petignat Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
Cameroon

Who might be able to join this trial: - You are willing to take part in the study and have given your free and informed agreement to do so Who may not be able to join: - You have never had sexual intercourse - You are pregnant at the time of your screening appointment - You have a condition that makes it difficult to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04865887 · Georgetown University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older who have been diagnosed with cervical cancer that has spread to nearby tissues or to other parts of the body, confirmed by a tissue test. - People whose cancer has gotten worse after at least one previous treatment, or who were unable to tolerate a pre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04901351 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇫🇷 FR

**Who might be able to join this trial:** - You have a long-lasting high-risk HPV infection that has continued for at least 6 months after treatment for a cervical or vaginal problem, OR you have had a return of a serious pre-cancerous condition or cancer in the cervix or vagina. - You have given your written agreement...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04910802 · Miriam Elfström Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇸🇪 SE

Who might be able to join this trial: - Women aged 22–26 years who live in the local area covered by the screening program - Women who have not opted out of the cervical screening program and who agree to take part in the study - Women who attend a screening appointment and agree to have an HPV (human papillomavirus) t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04929769 · Obstetrics & Gynecology Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cervical cancer (squamous carcinoma, adenocarcinoma, or squamous adenocarcinoma) at an early stage (Stage IB1, IB2, or IIA1) - People aged 21 to 70 years old - People whose planned surgery falls under a specific surgical...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04974346 · Zhejiang Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and have signed a consent form agreeing to join the study - Women aged 18 to 75 years old - People diagnosed with cervical cancer of a specific cell type: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma - People wh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04990076 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2026
🇧🇪 BE

Who might be able to join this trial: - People who are scheduled to have their uterus removed (hysterectomy) because of a growth or abnormality in the uterine muscle wall that is larger than 1cm (such as a fibroid, a localised area of adenomyosis, or a uterine sarcoma) Who may not be able to join: - People who do not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05027776 · Shanghai Bovax Biotechnology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 22 November 2023
🇨🇳 CN

Who might be able to join this trial: - Chinese females between 9 and 26 years old who are generally healthy, and who can provide valid identification. - People who are willing to take part in the study voluntarily; if the person is a minor, both the minor and their legal guardian must agree and sign a consent form. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05034991 · Far Eastern Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇹🇼 TW

"Who might be able to join this trial: - Women aged 20 years or older who have been diagnosed with endometrial cancer (a type of cancer affecting the lining of the uterus) Who may not be able to join: - Women who are under 20 years of age Important: Always verify eligibility with the trial site directly before applyi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05049538 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

Who might be able to join this trial: - Women aged 18 years or older - People who have been diagnosed with endometrial cancer confirmed by a tissue sample (biopsy or similar test) - People who are being considered for surgery as the main treatment, or who have recently had that surgery - People who are willing and able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05062707 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇳🇱 NL

**Who might be able to join this trial:** - You are between 18 and 39 years old at the time of your cancer diagnosis - You have been diagnosed with a confirmed cancer, which may include leukemia, Hodgkin or non-Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, or cervical cancer - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05078528 · Barretos Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 August 2025
🇧🇷 BR

Who might be able to join this trial: - Women who are older than 25 years of age. - Women who are having a colposcopy (a close examination of the cervix) because of an abnormal cervical screening result, or who are being monitored due to a history of abnormal cervical cells. - Women who could potentially become pregnan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05092022 · Milton S. Hershey Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇺🇸 US

Who might be able to join this trial: - People who are due or overdue for cervical cancer screening but have not had it done recently - People who can speak, read, and communicate well in English or Spanish - People who are not considered to be at higher-than-average risk for cervical cancer Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05102240 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇮🇳 IN

Who might be able to join this trial: - Patients who have been treated for cervical cancer using a combination of chemotherapy, radiation, and brachytherapy (internal radiation) as part of a clinical trial, and who have MRI or CT scan images available from the time of their diagnosis and brachytherapy treatment - Patie...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05103683 · TORL Biotherapeutics, LLC Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 August 2026
🇰🇷 KR🇺🇸 US

Who might be able to join this trial: - You have an advanced solid tumor (a cancer that has grown or spread and forms a solid mass, rather than a blood cancer). - Your cancer can be measured using standard imaging scans, according to a set of guidelines called RECIST v1.1. - You are generally able to carry out daily ac...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05112991 · 3D Medicines (Sichuan) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to participate and have signed a consent form. - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus), confirmed through laboratory testing of tissue, where the cancer is advanced, has come back, or has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05173272 · Sichuan Cancer Hospital and Research Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with cervical cancer (confirmed by laboratory tissue testing) of a specific type — adenocarcinoma, adenosquamous, or squamous cell — at a certain stage of the disease (FIGO 2018 stage Ib3 to IIIc2) (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05179447 · Women's Hospital School Of Medicine Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have had a hysterectomy (removal of the uterus) along with removal of the fallopian tubes, and lymph node removal or mapping in the pelvis, with or without removal of the ovaries or nearby lymph nodes near the aorta. - People whose cancer has been confirmed by a ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05186493 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇳🇴 NO

Who might be able to join this trial: - You must be an adult aged 18 or older - You have a locally advanced cancer in the pelvic area (the lower part of the abdomen) that requires a major surgery called pelvic exenteration, which involves removing several organs in that area - Your medical team has assessed that you ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05229679 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2038
🇸🇪 SE

Who might be able to join this trial: - You are a woman between the ages of 23 and 29 who has been invited to attend a screening appointment. Who may not be able to join: - Women who do not attend their screening appointment are not eligible. - Women who do not give their consent to take part are not eligible. Import...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05247268 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have agreed to take part and signed a consent form - You have been diagnosed with early-stage endometrial cancer (a specific low-risk type called endometrioid, grade 1, that has not grown into the muscle wall of the uterus), confirmed through a biopsy or similar procedure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05256225 · National Cancer Institute (NCI) Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 31 October 2027
Puerto Rico🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with HER2-positive endometrial cancer (including serous, clear cell, endometrioid, mixed, dedifferentiated/undifferentiated types, or carcinosarcoma) at any stage (IA through IVB), where the cancer has not come back and no chemotherapy has been given yet. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05282095 · Fujian Maternity and Child Health Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You are a woman aged 18 to 45 years old who wishes to become pregnant - You have been diagnosed with a specific type of cervical cell change (called HSIL/CIN2 or CIN2-3) confirmed by a cervical tissue biopsy taken within the last 3 months - You have not yet had any surgery, physi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05283330 · Orano Med Theranostics, SAS Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed (confirmed by tissue testing) with an advanced or spreading solid tumor, specifically one of these cancer types: prostate cancer that no longer responds to hormone treatment (including a specific subtype called neuroendoc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05283421 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇩🇰 DK

**Who might be able to join this trial:** - You are a woman aged 50 or older who has gone through menopause (meaning you have had no periods or bleeding for at least 1 year) - You have been referred for a colposcopy (a close-up examination of the cervix) because you tested positive for HPV and/or had an abnormal cervic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05284877 · Merete Haedersdal Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇩🇰 DK

**Who might be able to join this trial:** *For organ transplant recipients:* - You are 18 years of age or older - You have received a solid organ transplant (kidney, liver, lung, or heart) - You have been on a stable anti-rejection medication plan for at least 3 months - You are showing no signs that your body is curr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05286034 · International Agency for Research on Cancer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇫🇷 FR

Who might be able to join this trial: - Women aged between 30 and 65 years old - Women who have not had a pap smear in the last 4 years - Women living in disadvantaged areas within the Occitanie region of France - Women who did not respond to an initial letter inviting them to attend a clinic-based HPV test Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05316935 · Xiaojun Chen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed through a uteroscopy procedure with either a pre-cancerous thickening of the uterine lining (endometrial atypical hyperplasia) or a very early-stage, low-grade uterine cancer that has not grown into the uterine muscle wall - People with a body...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05367206 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2024
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a confirmed type of cervical cancer — specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cancer has been classified as FIGO (2018) stage IIIC, with a tumour larger than 4 cm and/or a lymph node large...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05371353 · Shanghai Bovax Biotechnology Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must have previously taken part in one of two specific HPV vaccine studies (either the study at Yangchun CDC with reference number 4-HPV-3001, or the bridging study at Mianyang CDC with reference number 4-HPV-3002), completed the full course of vaccine doses, and had a b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05372484 · M.D. Anderson Cancer Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
Mozambique🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 25 and 49 years old - You have recently had an abnormal cervical cancer screening result, such as an abnormal smear test, a positive VIA test, or a positive HPV test - You still have your cervix (it has not been removed) - You are not pregnant and have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05386615 · InSightec Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN🇺🇸 US

Who might be able to join this trial: - People who have symptomatic fibroids (fibroids causing noticeable symptoms) and meet the medical criteria for treatment with the Exablate device (confirm with trial site) - People who have already received fibroid treatment using the Exablate system and have agreed to be part of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05401175 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 60 years old. - People with cervical cancer where both radiation therapy and chemotherapy are considered appropriate treatments. - People whose cervical cancer has been confirmed by pathology to be squamous cell carcinoma, adenocarcinoma, or adenos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05405270 · Catharina Ziekenhuis Eindhoven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with a high-grade cervical cell change (called CIN2 or CIN3) that has been confirmed by a tissue biopsy - People with CIN2 who, after discussing watchful waiting with their doctor as recommended by Dutch guidelines, prefer to try imiquimod trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05406856 · Leiden University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, whether HPV-positive or HPV-negative) and whose treatment plan includes a combination of chemotherapy and radiation therapy followed by a special...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05413798 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇿🇦 ZA

Who might be able to join this trial: - People who have a confirmed HIV-1 infection - People who are 25 years of age or older - People who are willing and able to sign a written consent form to participate Who may not be able to join: - People who are pregnant or planning to become pregnant within 90 days of enrolling...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05421650 · CHA University Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇮🇳 IN🇮🇹 IT🇷🇴 RO🇰🇷 KR🇻🇳 VN

**Who might be able to join this trial:** - Women between 20 and 70 years of age - People newly diagnosed with a specific type of cervical cancer — either squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose scans (CT or MRI, sometimes PET-CT) show enlarged lymph nodes in the pelvis or ne...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05448365 · Lo.Li.Pharma s.r.l Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇮🇹 IT

Who might be able to join this trial: - People who have a uterine fibroid (a non-cancerous growth in the womb) that is at least 4cm in size, or who have more than one fibroid - People who have been assessed as suitable for surgery - People who experience symptoms such as heavy or irregular bleeding, or pain in the pelv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05472311 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 April 2026
Kenya

Who might be able to join this trial: - You are a policy maker involved in healthcare decisions - You are a health facility manager - You are a healthcare provider working at one of the reproductive health clinics taking part in this study - You are a woman aged between 25 and 60 years old who is coming to a participat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05492123 · Hospital Israelita Albert Einstein Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇧🇷 BR

**Who might be able to join this trial:** - Women over 18 years of age - People with a confirmed diagnosis of cervical cancer (either adenocarcinoma or squamous carcinoma) that is at a specific stage — either Stage IB2 or IB3 with cancer spread to nearby lymph nodes, or Stage IIB through IVA - People who have not previ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05500118 · Shenzhen Maternity & Child Healthcare Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with uterine fibroids (leiomyoma) through ultrasound and MRI scans, and who do not have symptoms from the fibroids - Women between 18 and 55 years of age - People whose largest fibroid measures less than 5cm across, and who have no more than 10...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05511623 · First Affiliated Hospital of Guangxi Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old - People who have been diagnosed with cervical cancer confirmed by tissue testing, specifically squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cervical cancer has been classified as 2018 FIGO stage IIIC2 - People w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05512208 · University of Oklahoma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older. - People with a confirmed diagnosis of certain gynaecological cancers (including endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or other solid gynaecological cancers) that have specific genetic changes — mutations in R...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05542407 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 21 February 2028
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and are willing to sign a consent form agreeing to take part in the study. - You are 18 years of age or older at the time of signing consent. - You are able to carry out daily activities with little to no limitation, or only moderate limitation (con...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05544084 · University of Illinois at Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
Senegal

**Who might be able to join this trial:** *All participants (Samples a, b, and c):* - People who are citizens of Senegal aged between 25 and 69 years old - People who are willing to take part in survey questions *Sample a (Advisory and Regional Team Members) — additional criteria:* - People who have been invited to b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05548296 · Acrivon Therapeutics Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 30 May 2027
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who are able to give signed, written consent to participate. - People who have been confirmed through a tissue sample (biopsy) to have high-grade endometrial (uterine) cancer. - For Arms 1 and 2: People with high-grade uterine cancer of various tissue types, including...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05554276 · Shanghai Jiao Tong University Affiliated Sixth People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with cervical squamous cell carcinoma (a specific type of cervical cancer) through a laboratory test, and whose cancer has been assessed by doctors as unable to be removed by surgery. **Who may not be able to join:** - People who have an active...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05559879 · University of Alabama at Birmingham Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with carcinosarcoma (a specific type of cancer) of a gynecologic organ, confirmed by a tissue sample test - You have already received at least one round of chemotherapy for your cancer - Your cancer can be measured or tracked using standard imaging sc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05570422 · Kortuc, Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 30 January 2027
🇮🇳 IN🇹🇭 TH🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to provide written consent to participate before the trial begins - Women aged 18 years or older - People who have been confirmed by tissue testing to have a specific type of cervical cancer (squamous cell carcinoma, adenocarcinoma, or adeno-s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05603910 · Aaron Wolfson Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of endometrial cancer (called pMMR) that has either come back after surgery alone, or that cannot be surgically removed, and where external beam radiation therapy has been identified as an appropriate treatment approach — w...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05606133 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 August 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with HPV-related high-grade cervical cell changes or cervical cancer, confirmed by a biopsy (a small tissue sample examined in a lab) Who may not be able to join: - People who do not meet the inclusion criteria listed above Import...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05610501 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇧🇪 BE🇨🇿 CZ🇮🇹 IT🇸🇪 SE

**Who might be able to join this trial:** - The tumor or lesion being biopsied must be safely reachable by a biopsy needle, with no organs or blood vessels in the way, and must have a solid portion (not purely fluid-filled cysts). For biopsies approached through the vagina, severe vaginal narrowing must not be present...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05634681 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇳🇴 NO

**Who might be able to join this trial:** - People who have been diagnosed with cervical cancer through a tissue biopsy, and whose cancer is planned to be treated with a combination of radiation and chemotherapy (rather than surgery as the main treatment) - People whose cancer falls within a specific stage range (FIGO...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05635123 · Women's Hospital School Of Medicine Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 20 and 75 years old - Women who have been newly and officially diagnosed with cervical cancer or endometrial cancer (confirmed by a tissue/pathology test) for the first time - Women who are attending a routine health check-up - People who are willing to gi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05639972 · Christian Hinrichs Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People whose cancer has been confirmed by laboratory testing to be from a specific primary tumor site and stage listed in the trial's protocol. - People whose tumor has been tested in a certified laboratory and confirmed to carry the HPV16 strain of the human papillomavirus....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05640700 · Hadassah Medical Organization Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇮🇱 IL

Who might be able to join this trial: - You are between 25 and 70 years old - You have come to the clinic for a Pap smear or a colposcopy (a closer examination of the cervix) Who may not be able to join: - You do not agree to having a sample collected - You have taken antibiotics at any point in the month before your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05646316 · NRG Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with endometrial (uterine) cancer confirmed by a tissue sample taken within the past 90 days, and who are planned to have a keyhole (laparoscopic or robotic) surgery to remove the uterus and check nearby lymph nodes as part of their treatment -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05647109 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with either atypical endometrial hyperplasia (abnormal cells in the lining of the uterus) or early-stage, slow-growing uterine cancer (Grade 1), confirmed by a procedure called a hysteroscopy, with no sign that the cancer has grown into the musc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05653063 · University College, London Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇮🇳 IN🇯🇴 JO🇲🇾 MY🇿🇦 ZA

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer (specifically in the oropharynx, larynx, hypopharynx, or nasopharynx) at an early to moderate stage (Stage I–III), confirmed by a tissue test, and who have agreed to receive full-dose radiation treatment aimed at curing the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05655260 · University of Helsinki Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇫🇮 FI

**Who might be able to join this trial:** - Adults aged 18 to 100 years - People whose general health and ability to carry out daily activities meets a standard medical rating of 0 to 2 (meaning they are fully active to capable of some self-care, confirm with trial site) - People diagnosed with early-stage (Stage I or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05675787 · Peking University People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed through a uterine examination (hysteroscopy) with either atypical endometrial hyperplasia (abnormal cells in the uterine lining) or early-stage, low-grade uterine cancer that has not grown into the uterine wall — this includes people who are ne...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05683041 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇧🇪 BE

Who might be able to join this trial: - People aged between 18 and 45 years old - People who have fibroids (non-cancerous growths in or on the uterus) of specific types and locations, and who are scheduled for surgery to remove them through keyhole surgery or open abdominal surgery - People who have been confirmed, thr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05687084 · Universita di Verona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with uterine (endometrial) cancer of any type or grade, including a type called carcinosarcoma - Your planned treatment includes surgery to remove the uterus and both ovaries and fallopian tubes (keeping the ovaries in certain cases does not prevent you fr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05691010 · Memorial Sloan Kettering Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 10 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with endometrial cancer (uterine cancer), including specific types such as endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma. - People who hav...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05709769 · Zhejiang Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have had a radical hysterectomy (removal of the uterus and surrounding tissue) and pelvic lymph node removal, with a confirmed diagnosis of cervical cancer - People whose cervical cancer was classified as stage IB1 to IIA2 using the 2014 FIGO cervical cancer stagi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05727228 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇩🇰 DK

Who might be able to join this trial: - Women aged 50–64 who have tested positive for HPV through a screening program - Women aged 23–64 who are having a follow-up test (HPV and cell sample) six months after a LEEP procedure (a treatment to remove abnormal cells from the cervix) in the Central Denmark Region - Women ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05735145 · Fourth Affiliated Hospital of Guangxi Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), confirmed by a tissue biopsy - Your cancer is at a locally advanced stage (classified as FIGO stage IB3, IIA2, IIB, III, or IVA based on 2018 guid...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05749887 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with cervical cancer at a specific stage (Stage Ib3, IIA2, IIB, III, or IVA using the FIGO 2018 staging system), with one of three specific cancer cell types: squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma. - People who have complet...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05758688 · Abramson Cancer Center at Penn Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with cervical or endometrial (uterine) cancer, confirmed through a tissue sample test - People whose doctors have recommended radiation therapy to the whole pelvic area after surgery or treatment, with or without additional cancer-fighting medicines...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05761561 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma (any stage), OR advanced or spreading endometrial cancer (including carcinosarcoma), AND whose treatment plan includes the chemotherapy drugs carboplatin and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05764044 · Hospital do Coracao Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with cervical cancer at a certain stage (moderately advanced to advanced, known as FIGO 2018 stage IB3 to IVA). - You have already received standard treatment combining chemotherapy and radiation therapy (chemoradiotherapy). - You are generally well enough...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05768139 · Eli Lilly and Company Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2030
🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT🇯🇵 JP🇳🇱 NL🇪🇸 ES +1 more

**Who might be able to join this trial:** - People who have an advanced, spreading, or inoperable solid tumour cancer (the specific type depends on which group within the trial a person is assigned to) - People who have a recent tumour biopsy available, or who are able to provide a suitable tissue sample before or at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05793333 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇮🇹 IT

Who might be able to join this trial: - People who have given written consent to participate - People who have been diagnosed with endometrial cancer that has been confirmed through laboratory testing of tissue samples - People who have had molecular and genetic testing done on their tumor (looking at specific markers...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05793749 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People with gynaecological cancer who are receiving radiotherapy after having lymph node surgery, and who agree to take part voluntarily by signing a consent form. - People aged between 18 and 60 years old. - People who are reasonably active and able to carry out daily activ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05795244 · Yonsei University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇰🇷 KR

**Who might be able to join this trial:** - People who have signed and dated a consent form after being fully informed about the trial. - People who are female. - People who are 20 years of age or older at the time of signing the consent form. - People who have been diagnosed with endometrial cancer or carcinosarcoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05797831 · Kartos Therapeutics, Inc. Phase 3 · 17 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2025
🇦🇹 AT🇨🇦 CA🇩🇰 DK🇪🇪 EE🇫🇮 FI🇬🇪 GE🇭🇺 HU🇮🇱 IL +9 more

**Who might be able to join this trial:** - You are generally healthy and able to carry out normal daily activities with little or no limitations (this is measured on a standard scale called ECOG 0-1) - You have been diagnosed with endometrial (uterine) cancer that has been confirmed by a lab test, and your cancer has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05808933 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with cervical cancer (confirmed by biopsy) at an early stage (FIGO stage IA to IIA) and are scheduled to have surgery for it. - People who are women aged 18 years or older. - People who have agreed to participate by signing an informed consent form....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05817214 · Zhongnan Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - A person must give their signed consent, or have a legal representative do so on their behalf. - Patients must be female, aged 18 to 75 years old. - Patients must have a good general physical functioning level, measured on a standard scale (ECOG score of 0 or 1 — confirm wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05819892 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have read and signed a consent form before any study procedures begin - People who have been surgically staged with Stage IIIC endometrial cancer (of any tissue type), confirmed by pathology, who are eligible for follow-up treatment combining radiation and chemoth...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05838521 · Yale University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have cervical cancer (of epithelial origin) that has been confirmed by a scan (CT or MRI) and has come back or not gone away after at least one prior chemotherapy treatment. - You have saved tumor tissue samples (from a previous biopsy or surgery) available for testing....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05848557 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
Kenya

**Who might be able to join this trial:** *For healthcare workers (including community health volunteers, clinic staff, supervisors, and Ministry of Health officials):* - People who are 18 years of age or older - People who are employed by a government clinic - People who are currently working in cervical cancer scree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05857631 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 May 2029
🇮🇳 IN

Who might be able to join this trial: - People who have a performance status score of 0 to 2 on a standard scale used by doctors to measure how well a person is able to carry out daily activities (confirm with trial site) - People who have been confirmed by tissue testing to have cervical cancer after having a hysterec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05872724 · Suzhou Municipal Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with cervical cancer that has been confirmed by a tissue sample and is at a specific stage of spread (Stage IB2 to IIA2 based on international staging guidelines). - You are 18 years of age or older. - You are in reasonably good general health and are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05876130 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with a specific type of uterine (womb) cancer called endometrioid endometrial cancer, confirmed through laboratory testing of tissue samples - People who have completed a hysterectomy (surgery to remove the uterus) along with surgical staging (surge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05903131 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with complex atypical endometrial hyperplasia (an abnormal thickening of the uterine lining) or early-stage (grade 1) uterine cancer, confirmed by a tissue biopsy — including those already receiving hormone treatment (progestin) to manage this...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05909111 · Recherche clinique Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇫🇷 FR

**Who might be able to join this trial:** - People who are older than 18 years of age - People who have been diagnosed with cervical cancer confirmed by a tissue sample (specifically squamous cell carcinoma, adenocarcinoma, or a mixed type) - People whose treatment plan involves a combination of radiation therapy and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05910177 · Fujian Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a woman between 18 and 75 years old - You have been diagnosed with cervical neuroendocrine carcinoma (a specific type of cervical cancer) confirmed by a tissue or cell sample — if it is a mixed cancer type, at least 60% must be the neuroendocrine type - Your cancer i...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05916196 · Abramson Cancer Center at Penn Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You have uterine cancer that has come back, spread to other parts of the body, or has not been treated with surgery, and this has been confirmed through a biopsy or standard medical scans (such as CT, PET/CT, MRI, bone scan, x-ray, or ul...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05937958 · UMC Utrecht Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇩🇰 DK🇳🇱 NL

Who might be able to join this trial: - People diagnosed with a newly confirmed (by biopsy) advanced-stage gynaecological cancer — not including ovarian cancer — or endometrial (uterine) cancer, where the treatment plan involves radiation therapy or combined chemotherapy and radiation aimed at curing the condition. - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05938192 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇮🇹 IT

Who might be able to join this trial: - You have a health condition caused by HPV (Human Papillomavirus) Who may not be able to join: - You have withdrawn or taken back your consent to take part in the trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05952141 · Abramson Cancer Center at Penn Medicine Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Botswana🇺🇸 US

Who might be able to join this trial: - People who are biological females - People who are 18 years of age or older - People who have been diagnosed with invasive cervical cancer, confirmed through pathology (laboratory tissue testing) - People whose pathology results were evaluated at the National Health Laboratory in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05952947 · HRYZ Biotech Co. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form agreeing to take part in the study. - People aged 18 to 75 years old. - People who have been diagnosed with a solid tumour that has spread or come back, and where testing has confirmed the tumour is infected with a virus called HPV18....

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05977621 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of cervical cancer (squamous, adenosquamous, or adenocarcinoma) or uterine adenocarcinoma that has either come back or cannot be treated with surgery, confirmed by a tissue biopsy. - People whose treatment plan includes radiatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05979493 · Joseph Findley MD Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2026
🇺🇸 US

Who might be able to join this trial: - You have uterine fibroids (non-cancerous growths in the womb) that need to be surgically removed, while keeping your uterus intact - You are willing and able to follow all the study's requirements for the full length of the trial - You are able to sign and date a consent form agr...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05979610 · University of Utah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a confirmed cancer of the uterus lining (endometrium), cervix, vagina, or vulva - People whose treatment plan includes a type of internal radiation therapy called brachytherapy, given as an outpatient (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05997017 · Aadi Bioscience, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or returning endometrioid endometrial cancer (a specific type of uterine cancer) that has been confirmed by a doctor. - People who have at least one measurable area of cancer that can be seen on a CT scan or MRI scan. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06004011 · Implenomics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
Zambia

Who might be able to join this trial: - You are between 15 and 39 years old at the time of joining the study - You have been taking HIV treatment medication (antiretroviral therapy) for at least 6 months - You do not have any plans to move away from your current home during the 3 years the study will run Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06022757 · Evopoint Biosciences Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a consent form before any study activities begin. - People aged 18 or older. - Cohort 3 (advanced prostate cancer group) is open to men only; all other groups have no gender restriction. - People with advanced solid tumours who fit int...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06038032 · University of Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇨🇦 CA

**Who might be able to join this trial:** - People who are 18 years old or older - People who have been diagnosed with a specific type of uterine cancer called low-grade endometrioid adenocarcinoma, at stages I to III (using FIGO 2009 staging) - People who finished surgery and any follow-up cancer treatment between 1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06042543 · International Agency for Research on Cancer Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US Zimbabwe

Who might be able to join this trial: - People who have not had cervical screening in the past 3 years - People between the ages of 25 and 49 years - People who understand and are willing to sign a consent form agreeing to take part Who may not be able to join: - People who do not wish to take part for any reason - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06056635 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are pregnant and have a condition that requires surgery performed while the baby is still in the womb - People who are medically cleared to receive anesthesia (the medication used to make patients unconscious or numb during surgery) - The pregnant person and, if availa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06078514 · Tampere University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇫🇮 FI

Who might be able to join this trial: - People aged between 18 and 70 years old - People attending their first colposcopy appointment, or whose last colposcopy was more than 24 months ago - People referred for the colposcopy due to abnormal cervical screening results or repeated positive HPV test results - People who h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06082765 · Zhongnan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are planning to have cervical screening done - People who have a regular menstrual cycle that comes every 21 to 35 days - People who agree to take part in the study and have signed a consent form Who may not be able to join: - People who have stopped having periods or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06083103 · Centre Paul Strauss Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 September 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People with suspected cervical cancer at a moderate to advanced stage (stages IB2 to IVA), based on clinical information and an MRI scan of the pelvis, who are in the process of being assessed before treatment begins - Women who could become pregna...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06093438 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been newly diagnosed with locally advanced cervical cancer (not yet treated) and the diagnosis has been confirmed by a tissue sample (biopsy) - Your cancer is at a specific advanced stage (2019 FIGO stage IIIB–IVA), or if stage IIIC, the affected lymph nodes must mea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06096688 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 May 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with a hereditary cancer syndrome (based on genetic testing or clinical criteria) and are scheduled for a scope procedure of the digestive tract or a uterine lining screening procedure - People coming t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06102863 · Peking University People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - Your diagnosis is either atypical endometrial hyperplasia (abnormal cells in the uterine lining) or a very early-stage, low-grade form of uterine cancer (stage IA, well-differentiated endometrioid adenocarcinoma). - A scan (MRI) before treatment showed the cancer has not spr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06123884 · Bio-Thera Solutions Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - Women aged 18 to 70 years who are willing to sign a consent form to take part - People with cervical cancer that has come back, never fully went away, or has spread to other parts of the body (classified as FIGO Stage IVB), confirmed by a tissue test (pathology report requir...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06129253 · International Vaccine Institute Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
Bangladesh Democratic Republic of the Congo Ghana Nepal🇵🇰 PK Sierra Leone Tanzania Zambia

Who might be able to join this trial: - People between 9 and 50 years old at the time of joining the trial - People who have been living in the selected community for at least the past 3 months (exceptions may apply for pastoralists, refugees, and commercial sex workers) - People who are able to understand what the stu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06140589 · Fujian Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have cervical cancer that has come back, kept growing during treatment, or spread to other parts of the body - People whose cervical cancer is one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People who do not have any othe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06142760 · Juergen Debus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with cervical cancer confirmed by a biopsy, specifically squamous-cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma - People whose cervical cancer has been classified at a specific stage (FIGO stage IB, IIA, IIB, IIIA, IIIB, or IIIC1)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06143631 · University of California, San Francisco Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 6 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 21 years old and under 54 years old - People who were identified as female on their birth certificate - People who have had fibroids (uterine leiomyomata) confirmed by an ultrasound or MRI scan within the past 24 months - People who have experienced f...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06147960 · Centre Hospitalier Universitaire de Nīmes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - People who were treated with a combination of radiotherapy and chemotherapy (and no surgery) for locally advanced cervical cancer, classified as stage Ib to IVb under the FIGO staging system. - People who are 18 years of age or older. - People who have had at least 2 years of fol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06157151 · Precigen, Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 11 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older. - People who have cervical cancer that has come back or spread to other parts of the body, confirmed by a tissue or cell sample. - People who have already received treatment with a medicine called pembrolizumab (either alone or combined with ot...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06169449 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with endometrial cancer or a condition called atypical hyperplasia (an abnormal thickening of the uterine lining) - People whose tissue samples have been tested using specialised laboratory methods (immunohistochemica...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06182241 · Boston University Charles River Campus Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇿🇦 ZA🇺🇸 US

**Who might be able to join this trial:** - You have a cervix - You are 18 years of age or older - You are living with HIV - You have had an abnormal Pap smear result that was classed as high-risk, taken within the last month (in some cases, results from up to 6 months ago may be accepted) **Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06191133 · Lindsay Ferguson, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have high-grade abnormal cells (dysplasia) or cervical cancer, specifically of the squamous cell, adenocarcinoma, or adenosquamous cell carcinoma types - People whose condition is being managed with one of these proc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06206083 · National Institute of Cancerología Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇲🇽 MX

Who might be able to join this trial: - People who have been clinically diagnosed with a specific type of uterine (endometrial) cancer called endometrioid-type endometrial cancer, and who have tissue samples available. - People who have had surgery at INCan (the National Cancer Institute in Mexico). Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06209294 · Xiaohua Wu Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a written consent form to participate. - People aged 18 to 45 years old at the time of joining the trial. - People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale call...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06230549 · University Hospital, Essen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2024
🇩🇪 DE

Who might be able to join this trial: - You have a good general level of physical fitness and are able to carry out normal daily activities with little or no limitation (this is measured using a scale called ECOG, scored 0 or 1) - Your diagnosis has been confirmed by a tissue sample (biopsy) examined under a microscope...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06251388 · West China Second University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to give written consent to participate. - Women between 18 and 75 years of age. - People whose doctors estimate they are likely to survive for at least 3 months. - People who have been confirmed by laboratory testing (tissue or cell samples) to hav...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06253494 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer confirmed by a tissue test (biopsy). - People whose cancer has spread to other parts of the body or has grown into nearby areas, confirmed by imaging scans. - People whose cancer can be measured or tracked on scans using...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06254846 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - People who are female - People aged between 30 and 65 years old - People attending a Gynecology-Obstetrics department for a routine first-time cervical cancer screening appointment - People who are covered by or entitled to a social security scheme - People who have been informed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06256224 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been recently diagnosed with a type of cervical cancer called squamous cell carcinoma that has not been treated before - Your cancer is locally advanced (at a certain stage of spread within the pelvic area) but has not spread to dis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06260358 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who have a confirmed diagnosis of cervical cancer proven by a biopsy, at any stage of the disease - People who have agreed in writing to allow their personal data to be used for research purposes Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06266338 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older at the time of signing the consent form - People with a laboratory-confirmed diagnosis of squamous, adenocarcinoma, or adenosquamous cervical cancer that has come back or spread to other parts of the body - People who have received up to 2 previous rou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06268626 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇦 CA

**Who might be able to join this trial:** **For Part A (initial study):** - You are 40 years of age or older - You are experiencing unusual uterine bleeding that has no known cause (not related to a coil/IUD or similar device) - You still have your uterus - You have been referred by a doctor to have a tissue sample ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06269809 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇧🇪 BE🇫🇷 FR🇳🇱 NL

Who might be able to join this trial: - People who have given voluntary written consent to participate before any screening takes place (or whose legal representative has done so on their behalf) - People who are using a highly effective form of contraception, such as implants, injections, combined oral contraceptive p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06276309 · Fujian Maternity and Child Health Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with neuroendocrine carcinoma of the cervix (a specific type of cervical cancer), confirmed through laboratory testing of tissue samples - People whose medical records and clinical information are complete Who may not be able to join: - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06288360 · Tongji Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with cervical cancer at a specific stage (FIGO 2018 stage IB3, IIA2, IIB, or IIIC1r with a tumour larger than 4 cm) who have not yet received any treatment, with staging confirmed by two qualified gynaecological specialists - People who have at least one tum...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06288373 · Tongji Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2031
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with locally advanced cervical cancer at a specific stage (FIGO 2018 stages IB3, IIA2, or IIB with a tumour larger than 4 cm), confirmed by two qualified doctors using physical examination and imaging. - People who have at least one tumour that can be measur...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06289062 · Tongji Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stage IB1 cervical cancer based on a physical examination and MRI scan - People whose cancer type has been confirmed by a tissue sample as squamous cell carcinoma of the cervix - People whose cervical transformation zone (the area where ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06289751 · Tongji Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with untreated stage IB2 cervical cancer (confirmed by two senior doctors using examination and imaging) - You have at least one tumour that can be measured on a scan (mainly MRI) - Your cervical cancer has been confirmed by a tissue sample (biopsy) a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06291311 · University Hospital Tuebingen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years of age or older - A swab test has detected a virus (HPV) using either mRNA or DNA testing (results from outside this trial site may also count) - A specific area of the cervix called the transformation zone, and the edges of any affected areas, are clearly v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307886 · Gaziosmanpasa Research and Education Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
Turkey (Türkiye)

Who might be able to join this trial: - You are considered a suitable candidate for keyhole (laparoscopic) surgery by your doctors - You are between 18 and 75 years old - You have been diagnosed with endometrial (womb) cancer at an early stage (FIGO stage 1 or 2, meaning the cancer has not spread far beyond the womb)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06315257 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older who have been diagnosed with advanced HPV-positive cervical cancer (stage IB1 to IVA) and have completed their primary treatment (such as surgery, radiation, and/or platinum-based chemotherapy) within the last 12 months. - People currently receiving a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06331468 · Denise Fabian Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇺🇸 US

Who might be able to join this trial: - People who have been newly diagnosed (not yet treated) with cervical cancer confirmed by a laboratory test, at a specific advanced stage (FIGO 2018 Stage IB3, II, IIIA–IIIC1 with a tumour 6cm or larger, Stage IVA, or Stage IVB), where the cancer has not spread so extensively that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06348719 · Rennes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - People diagnosed with low-risk or intermediate-risk uterine (endometrial) cancer of a specific type (endometrioid adenocarcinoma, grade 1 or 2), confirmed by biopsy and MRI scan, and classified as stage I before treatment. - People whose surgeon has recommended a minimally i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06349148 · SHUANG ZHENG JIA, PhD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older - People whose cancer has been confirmed by a tissue sample (biopsy) as one of these types of cervical cancer: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cervical cancer has been confirmed as locally advanced (meanin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06354738 · University Hospital, Gasthuisberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇧🇪 BE

Who might be able to join this trial: - People who have given their voluntary written agreement to participate (or whose legal representative has done so) before any screening begins - Women aged 18 years or older - People who have recently received their first-ever diagnosis of endometrial cancer (a type of uterine ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06360653 · ARNAS Civico Di Cristina Benfratelli Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are between 18 and 80 years old - You are generally able to carry out daily activities and care for yourself (your doctor will assess this using a standard scale) - You have been diagnosed with endometrial (uterine) cancer of a specific type (endometrioid, serous, clear c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06365905 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are 55 years of age or older - People who have had at least one episode of bleeding after menopause - People who have had an endometrial biopsy (a small tissue sample taken from the lining of the womb) performed at Mayo Clinic (Minnesota, Arizona, or Florida), a Mayo C...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06366347 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with a specific type of uterine cancer — either endometrioid endometrial cancer, or endometrial carcinosarcoma with an endometrioid component — confirmed through a tissue biopsy. - People whose cancer tests positive for estrogen receptors (ER-positive), mean...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06369155 · Joyce Liu, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with uterine serous carcinoma (a type of uterine cancer) that has come back or has not gone away, confirmed by a lab test on tumour tissue. - People who have at least one tumour that can be measured using standard imaging criteria. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06394297 · Fundacao Champalimaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 August 2025
🇵🇹 PT

Who might be able to join this trial: - People diagnosed with cervical cancer that is considered suitable for treatment with a combination of radiation and chemotherapy aimed at curing the disease. - People whose biopsy has confirmed one of three specific cancer types in the cervix: squamous-cell carcinoma, adenocarcin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06398938 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You are reasonably active and able to care for yourself, with little or no limitation in daily activities (this is measured on a scale used by doctors called ECOG, scored 0–2) - You have been diagnosed with a specific type of cervical cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06409052 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 August 2026
🇺🇸 US

Who might be able to join this trial: - Women who have been diagnosed with endometrial (uterine lining) cancer and are being seen at MD Anderson Cancer Center or its Houston-area locations - Women who have been diagnosed with abnormal uterine bleeding or endometrial hyperplasia (a thickening of the uterine lining) and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413992 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older. - People whose general health and ability to carry out daily activities meets a certain standard (rated 0–2 on a medical scale called ECOG), with a life expectancy of at least 6 months. - People who have been newly diagnosed with advanced (stage III...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06416150 · Fox Chase Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - People between 18 and 90 years of age (for women over 65, eligibility depends on screening and medical history) - People who have been referred for a colposcopy (a close examination of the cervix) at one of the trial's clinic sites - People who can communicate comfortably in Engl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06417736 · Women's Hospital School Of Medicine Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 45 years old and strongly wish to preserve your ability to have children in the future - You have been diagnosed through a tissue sample (biopsy) with a lower-grade form of uterine (endometrial) cancer or abnormal uterine lining growth (grade 1 or grade...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06420427 · The Third Affiliated Hospital of Guangzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been newly diagnosed with HPV-positive cervical cancer at any stage (I through IV) and have not yet had surgery, radiation therapy, or chemotherapy. - People who are older than 18 years of age. - People whose cervical cancer has been assessed as suitable for surge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06433817 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 May 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with cervical cancer confirmed by a pathology test (such as a biopsy) - People who are being treated with a combination of chemotherapy and radiation therapy at the same time - People who have had a special type of CT scan called a Spectral CT, take...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06435663 · The Fourth Affiliated Hospital of Zhejiang University School of Medici... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been clinically diagnosed with uterine fibroids (located within the muscle wall, or growing on the inside or outside of the uterus, classified as FIGO types 2–6) or adenomyosis (a condition where the uterine lining grows into the muscle of the uterus) - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06458062 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
Kenya

Who might be able to join this trial: - You are a woman between 30 and 64 years old, OR a woman living with HIV who is at least 25 years old - You have tested positive for HPV (human papillomavirus) in the last 6 months Who may not be able to join: - You are currently pregnant - You have had a negative HPV test in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06459687 · Lee's Pharmaceutical Limited Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and have signed a written consent form before any study procedures begin. - Women between 18 and 75 years of age at the time of signing the consent form. - People who have a good general physical functioning level, rated as fully a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06462378 · University of Aarhus Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 May 2029
🇩🇰 DK

**Who might be able to join this trial:** - You have cervical cancer that doctors believe can be treated with the goal of curing it, using radiation therapy (with or without chemotherapy), including a specialised type of internal radiation - Your biopsy has confirmed one of three specific types of cervical cancer: squa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06463028 · Faeth Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of uterine cancer called endometrioid endometrial carcinoma, confirmed by laboratory testing of tissue. - People whose cancer has spread or come back and cannot be treated with surgery or radiation with the goal of a cure. - Peo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06481592 · Iovance Biotherapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by lab testing to have endometrial carcinoma (cancer of the lining of the uterus), including a type called carcinosarcoma — but not uterine sarcoma. - People who have received between 1 and 4 previous systemic (whole-body) cancer treatments, wi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06489795 · Hannover Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2033
🇩🇪 DE

**Who might be able to join this trial:** - People diagnosed with a specific type of cervical cancer (adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma), confirmed through laboratory testing of tissue - People with early-stage cervical cancer classified as FIGO stage IA2, IB1, or IB2, with a tumour s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06501846 · Imperial College Healthcare NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 July 2027
🇬🇧 GB

Who might be able to join this trial: - Women who have experienced bleeding after menopause and need an endometrial biopsy (a small tissue sample taken from the lining of the womb). - Women whose bleeding meets the definition of post-menopausal bleeding — meaning bleeding that occurs at least one year after their last...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06502743 · Yonsei University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇰🇷 KR

**Who might be able to join this trial:** - Women aged 19 or older. - People who have had their cancer type confirmed by a tissue sample (biopsy), with one of these specific types: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, car...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06509724 · Samsung Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with cervical cancer confirmed by a tissue biopsy (histological diagnosis) - People whose cervical cancer is one of these specific types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People who have already had surgery...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06518564 · Panagiotis Konstantinopoulos, MD, PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have endometrial cancer with a specific genetic change called an ARID1A loss-of-function mutation, confirmed by an approved genetic test and verified by the lead doctor before joining. - People who have at least one tumour that can be measured using scans or physi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06522828 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have been diagnosed with advanced endometrial cancer or platinum-resistant ovarian cancer (a type of ovarian cancer that has stopped responding to platinum-based chemotherapy) - People who have a good general level of physical...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06524583 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of uterine cancer called uterine leiomyosarcoma, confirmed by a tissue sample taken less than 8 weeks before joining the study - People who are generally well enough to carry out daily activities with little or no limitatio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06527157 · PinkDx, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇺🇸 US

Who might be able to join this trial: - People who have signed and dated a consent form showing they have been told about all important aspects of the study. - People who are willing and able to attend scheduled visits and follow the study plan. - People who expect to be available for the full length of the study and c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06527456 · Centre Hospitalier Intercommunal Creteil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇫🇷 FR

Who might be able to join this trial: - Women aged 25 to 65 who live in the Île-de-France region of France - Women who are eligible for cervical cancer screening — meaning they have not had a hysterectomy (removal of the uterus) and are not currently being monitored for a pre-cancerous or cancerous condition of the cer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06528184 · National Healthcare Group Polyclinics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇬 SG

Who might be able to join this trial: - Women who are between 30 and 69 years old and are Singapore citizens - Women who are due for a cervical cancer screening - Women who have had sexual intercourse before - Women who are able to give informed consent to take part in the trial - Women who are able to read and communi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06532539 · Shandong Cancer Hospital and Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a written consent form before any trial-related procedures begin. - Women aged 18 to 80 years old. - People who are generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level requir...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06536517 · Johns Hopkins University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have a uterus - People aged 18 years or older - People scheduled to have their uterus removed using a minimally invasive approach (either laparoscopic, which uses small cuts in the belly, or robotic surgery), while keeping their ovaries - People having this surgery for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06538337 · Jonsson Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 July 2031
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with endometrial (uterine) or cervical cancer, confirmed by a laboratory test on a tissue sample - You have had surgery to remove the main tumor - Your cancer is at a stage where the standard recommended treatment after surgery is radiation therapy to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06544720 · The Affiliated Hospital of Qingdao University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People whose cancer is linked to HPV (Human Papillomavirus) - People who have at least one tumor or lesion that can be measured using standard imaging guidelines - People who are generally able to carry out normal daily activities with li...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06552598 · Tongji Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - **Phase I:** Women with gynecological cancers that have continued to grow or spread after standard treatments, and for whom no other effective treatment is available, aged 18 to 75 years old. - **Phase II:** Women of reproductive age (recommended age 40 or under) who want to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06558682 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with squamous cell carcinoma of the cervix (a specific type of cervical cancer affecting the outer cells of the cervix) - People whose cancer tests positive for HER-2 (a protein found on some cancer cells that can affect how the cancer gr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06560697 · National Institute of Cancerología Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇲🇽 MX

**Who might be able to join this trial:** - People with cervical cancer who are older than 18 years of age. - People who are willing and able to sign a consent form before taking part in any study-related procedures. - People who are able to attend scheduled visits, follow treatment schedules, complete lab and imaging...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06561308 · Women's Hospital School Of Medicine Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stage III (not yet able to be removed by surgery) or stage IV endometrial cancer, confirmed through imaging - People whose cancer has been confirmed by tissue testing to be a type called endometrial carcinoma - People aged 18 to 75 years o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06562166 · Peking Union Medical College Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been confirmed through laboratory testing to have cervical cancer of a specific type called squamous cell carcinoma - People whose cervical cancer has been staged (using the 2018 FIGO system) as Stage Ib3, II, IIIB, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06584032 · Hutchmed Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 8 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood and voluntarily signed the consent form for the trial - People aged 18 to 75 years (inclusive) with a body mass index (BMI) of 18.5 or above - People with advanced or returning endometrial (uterine) cancer that has been confirmed by a tissue...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06598176 · Universiteit Antwerpen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇧🇪 BE

Who might be able to join this trial: - People who are female and between 25 and 64 years old - People who have been diagnosed with cervical cancer (CIN3 or above, at any stage) or who need a procedure called a conization (a procedure to remove tissue from the cervix, for any reason) - People who have not yet started a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06603506 · Centre Francois Baclesse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 October 2027
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with endometrial (uterine) cancer that has not spread beyond the uterus, confirmed by a tissue sample (biopsy), and who are being considered for surgery - People whose endometrial cancer falls into one of the followin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06611020 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇮🇹 IT

Who might be able to join this trial: - People who are being treated for a disease caused by the Human Papillomavirus (HPV), which is a common virus that can cause certain infections and health conditions. Who may not be able to join: - People who have previously received an HPV vaccine (such as Gardasil or Cervarix)....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06619002 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇮🇹 IT

Who might be able to join this trial: - Women who are having minimally invasive surgery to remove sentinel lymph nodes as part of treatment for uterine (endometrial) or cervical cancer - A video recording of the surgery must be available - People aged 18 years or older - People who are willing to take part in the study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06632431 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇪🇬 EG

**Who might be able to join this trial:** - You were diagnosed with uterine (endometrial) cancer and had surgery to remove your uterus, ovaries, and fallopian tubes between January 1, 2018, and December 31, 2022. - Your medical records from the time of diagnosis onwards are available and include at least 2 years of fol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06640283 · Instituto do Cancer do Estado de São Paulo Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇧🇷 BR

**Who might be able to join this trial:** - People who have been diagnosed with cancer of the anal canal or cervix, confirmed by a tissue sample (biopsy). - People whose cancer has been found to be linked to HPV (Human Papillomavirus). - People whose cancer is contained within the local area — specifically, anal canal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06641531 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇪🇬 EG

Who might be able to join this trial: - Women between the ages of 21 and 60 who are sexually active and not currently pregnant - Women who have not had a pap smear done in the last 3 years - Women who have previously had an abnormal pap smear result and are coming in for a follow-up Who may not be able to join: - Wome...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06644248 · Bangladesh University of Engineering and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 January 2025
Bangladesh

**Who might be able to join this trial:** - Women aged 18 years or older - People who are willing to take part in cervical cancer screening - People who are available to have a colposcopy examination (a close examination of the cervix) - People who have not had a hysterectomy (surgical removal of the uterus) - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06656949 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been diagnosed with epithelial ovarian cancer (a specific type of ovarian cancer confirmed by laboratory testing) - People whose doctors expect them to live for more than 3 months - People who are willing and able to s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06658145 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Women aged 60 years old or younger - Women who need a full removal of the uterus (with or without removal of related structures such as the fallopian tubes or ovaries) because of uterine fibroids (non-cancerous growths in the uterus) - Women with a body mass index (a measure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06666192 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - Your local health clinic is part of this study if it provides preventive health care to residents in specific targeted neighborhoods - Healthcare workers (such as doctors, nurses, nurse practitioners, or physician assistants) and office staff who work at a participating clini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06669533 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 November 2026
Cameroon

Who might be able to join this trial: - People who have been diagnosed with a Type 3 transformation zone (a specific finding on cervical examination) confirmed before the start of the trial - People aged 25 years or older Who may not be able to join: - People who have a Type 1 or Type 2 transformation zone (different...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06671548 · Qilu Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 12 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - Women who have not yet gone through menopause and are 18 years of age or older - People who have been confirmed to have uterine fibroids (non-cancerous growths in the uterus) through an internal ultrasound scan during the screening period - People whose uterine fibroids are c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06673680 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇪🇬 EG

Who might be able to join this trial: - Women between the ages of 30 and 64 years old. - Women experiencing symptoms such as unusual white discharge, bleeding after sex, or bleeding between periods. - Women whose cervix has been noted by a doctor to appear unhealthy, such as showing signs of erosion, bleeding when touc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06680739 · Vall d'Hebron Institute of Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2032
🇪🇸 ES

**Who might be able to join this trial:** - People aged over 18 years at the time of joining the study. - People who are well enough to carry out daily activities with little to no limitation (measured by a standard scale called ECOG, with a score of 0 or 1). - **For Group 1:** People with confirmed advanced or return...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06680791 · Lukas Vanek Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇿 CZ

Who might be able to join this trial: - People who have been clinically diagnosed with endometrial cancer (cancer of the lining of the uterus). - People who have had surgery to remove the uterus, along with appropriate procedures to determine the stage of the cancer. Who may not be able to join: - There are no exclusi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06686043 · Baylor College of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with locally advanced or metastatic cervical cancer (Stage IB2–IVB), vaginal cancer (Stage II–IVB), or vulvar cancer (Stage II–IVB), and surgery is not considered your primary treatment option. - Your cancer can be measured on imaging scans, and you h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06689956 · Mayo Clinic Not Applicable · 10 countries Recruiting
Recruiting Not Applicable Est. completion 31 October 2029
🇦🇹 AT🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇪🇸 ES +2 more

**Who might be able to join this trial:** - People diagnosed with low-risk endometrial (uterine) cancer of a specific type called endometrioid, graded as grade 1 or 2, and classified as an early stage (stage IA under older staging guidelines, or stages IA1/IA2 under newer guidelines) - People whose cancer shows no sig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06692166 · Mabwell (Shanghai) Bioscience Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 9 December 2027
🇨🇳 CN

Who might be able to join this trial: - Women between 18 and 75 years old (inclusive) who are able to understand, agree to, and sign the trial consent form. - People who are generally able to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, with a score of 0...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06692335 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 June 2027
Hong Kong

**Who might be able to join this trial:** - People aged 18 to 50 years old - People who are pre-menopausal or in the early stages of menopause, with a hormone level (FSH) below 25 mIU/ml - People with a body mass index (BMI) under 33, or where the tissue layer of the abdominal wall measures less than 5 cm - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06705075 · Thomas Jefferson University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Women who have been diagnosed with endometrial cancer and are scheduled for a procedure called UAE (uterine artery embolization) - Women who are over 18 years of age - Women who could potentially become pregnant must have a negative pregnancy test result before joining - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06708429 · San Raffaele University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2033
🇮🇹 IT🇺🇸 US

Who might be able to join this trial: **For people with Lynch syndrome:** - Adults aged 18 or older - People of any sex - People who have already been diagnosed with Lynch syndrome through standard medical care, confirmed by a genetic change in one of these genes: MLH1, MSH2, MSH6, PMS2, or EpCAM - People with Lynch s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06712472 · Gustave Roussy, Cancer Campus, Grand Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2030
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer (uterine cancer) confirmed by a tissue sample, including specific types such as endometrioid, serous, clear cell, de-/undifferentiated carcinomas, or uterine carcinosarcoma (all grades accepted) - People whose cancer has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06726291 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who are 18 years of age or older, able to understand the study procedures, and willing to provide written consent to participate - People who have been diagnosed with endometrial cancer, confirmed through a tissue or cell sample - People with a general health and activ...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06727617 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, have been fully informed about the study, and are able to follow all trial procedures. - Women aged 18 to 65 years at the time of signing the consent form. - People with a general health and activity level rated as 0 or 1 on a stan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06741150 · Newish Technology (Beijing) Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** This trial has two groups (Cohort A and Cohort B) with different criteria. **Cohort A (for people with HPV16 infection and cervical cell changes):** - Women between 18 and 60 years of age - People who tested positive for HPV16 during screening (other HPV types can also be pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06746428 · Inova Health Care Services Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with endometrial (uterine) cancer of any type, at Stage I through Stage IVA - You have already had surgery to remove your uterus (a modified radical or radical hysterectomy) - You are planning to receive radiation the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06749847 · International Agency for Research on Cancer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇫🇷 FR

Who might be able to join this trial: - You are a woman between 30 and 65 years old - You live in the Marne or Aube departments in France - You are due for routine cervical cancer screening and have received your first invitation letter (not a reminder letter) for this screening round Who may not be able to join: - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06758557 · Huabo Biopharm Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old (including those who are exactly 18 or 75) - People who are able to fully understand the study, sign a consent form willingly, and follow the study procedures and scheduled visits - **During the dose escalation phase — Non-small cell lung cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06771193 · MSD Italia S.r.l. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇮🇹 IT

Who might be able to join this trial: - The patient (or their legal representative) must have signed and dated the required consent and privacy form. - The person must be 18 years of age or older. - The person must have a diagnosis of cervical cancer. - The cancer must be either locally advanced (meaning surgery to cur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06774209 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 70 years old - People who are willing and able to provide written consent to participate - People who are able to attend follow-up appointments - People for whom surgery or a biopsy is possible, in order to confirm a final diagnosis Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06774482 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇮🇹 IT

Who might be able to join this trial: - Female patients aged 18 or older who have been diagnosed with a cancerous tumour of the uterus (either a new or previous diagnosis dating back to 1 January 2000 or later), and who have received treatment at the Radiotherapy Unit of Sant'Orsola Polyclinic - People who have given t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06795009 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2029
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with recurrent high-grade uterine or endometrial cancer (specific types: grade 3 endometrioid, serous, or mixed high-grade) or uterine carcinosarcoma, whose cancer has come back or worsened after platinum-based chemotherapy, or who could not tolerate platinu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06804135 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇮🇳 IN

Who might be able to join this trial: - People aged 18 years or older. - People whose overall health allows them to complete a full course of pelvic radiation therapy, with or without chemotherapy or internal radiation (brachytherapy). - People who are able to understand the study information and are willing to sign a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06805019 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2024
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with uterine sarcoma (a type of uterine cancer) or uterine myoma (a non-cancerous growth in the uterus), confirmed by tissue testing - People who had a CT scan done for diagnostic reasons no more than 30 days before their surgery - People aged betwe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06815939 · DL Analytics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
El Salvador

Who might be able to join this trial: - Women between 30 and 59 years of age Who may not be able to join: - Women who are pregnant at the time of the colposcopy or biopsy procedure - Women who have had a hysterectomy where the cervix was also removed - Women who have had an HPV test at any point in the last 5 years, w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06836869 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2032
🇨🇳 CN

**Who might be able to join this trial:** - Women between 18 and 65 years of age - People with a laboratory-confirmed diagnosis of cervical cancer, specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cervical cancer has been classified as FIGO 2018 stage IB2 - People whose c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06840418 · Obstetrics & Gynecology Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with primary cervical cancer at stages I to III, with any type of cervical cancer cell type accepted - People aged 18 to 75 years old - People who have already had a radical or modified radical hysterectomy (surgical removal of the uterus and s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06841653 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2026
🇮🇹 IT

Who might be able to join this trial: - People who are over 18 years of age - People who have been diagnosed (confirmed by tissue testing) with endometrial hyperplasia (thickening of the uterine lining), endometrioid adenocarcinoma of the endometrium (a type of uterine cancer), or who have a healthy uterine lining and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06845982 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - People over 18 years of age who are patients at CHU de la Conception and need surgery for uterine smooth muscle tumours (such as fibroids or similar tumours) - People who are able to provide written consent to participate - People who are covered by a French social security s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06859775 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments - Women between 18 and 75 years old - People whose doctors expect them to live for at least 12 weeks - People whose major organs (such as hea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06862102 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇮🇹 IT

Who might be able to join this trial: - Your cervical smear (Pap smear) test showed abnormal cells that a doctor has recommended need further investigation with a colposcopy (a closer examination of the cervix) and an HPV test - You have an abnormal lesion (unusual tissue growth) on your vagina or vulva that is linked...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06867445 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with vaginal or cervical cancer that has come back or has not gone away after treatment - Your cancer has been confirmed by a tissue sample (biopsy) to be one of three specific types: squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06870903 · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hosp... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been newly diagnosed with early-stage endometrial (uterine) cancer (stages 1 or 2 under the FIGO 2023 classification system) where scans such as CT, MRI, or PET/CT show the cancer appears to be confined to the uterus. - People who do not have any other active...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06877572 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People with a body mass index (BMI) of 30 or higher (a measure of body weight relative to height) - People who have completed surgery to check the extent of their cancer, with no signs of remaining disease - People diagnosed with a specific type of uteri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06882824 · University Hospital, Clermont-Ferrand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 April 2027
🇫🇷 FR

Who might be able to join this trial: - People aged 18 to 43 years old - People who have fibroids (benign uterine growths) causing symptoms such as heavy bleeding, pain, or difficulty getting pregnant - People whose fibroids are suitable for keyhole (laparoscopic) surgery — meaning the largest fibroid is 10cm or smalle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06890273 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇩🇪 DE

Who might be able to join this trial: - Women aged 18 or older at the time of screening. - People who have been diagnosed with either advanced endometrial cancer (uterine cancer) at a late stage, or endometrial cancer that has come back and cannot be cured, where the medical team has decided that drug treatment is the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06893861 · National Cancer Institute, Naples Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇮🇹 IT

Who might be able to join this trial: - People who are female - People aged between 50 and 80 years old - People who are willing to take part in the study and sign a consent form agreeing to participate - People who are post-menopausal (meaning their periods have permanently stopped) Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06914297 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 45 years of age - People who have been diagnosed with a specific type of uterine cancer called endometrioid carcinoma (low-grade, G1 or G2) confirmed by a tissue sample taken through biopsy, scraping of the uterine lining, or a camera procedure inside t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06925724 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic or returning endometrial cancer (including types such as endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma, or carcinosarcoma) or cervical cancer (including squamous cell carci...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06935305 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 September 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with endometrial cancer confirmed through laboratory testing of tissue samples - People whose cancer appears to be at an early stage (Stage I or II) based on assessments done before surgery - People who are planned to undergo full surgical treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06942416 · Shandong Cancer Hospital and Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - Women aged 18 to 75 years who have given written consent before any trial procedures begin - People with cervical cancer that has been confirmed by a tissue or cell sample, specifically one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06952660 · Pfizer Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 13 December 2028
Puerto Rico🇺🇸 US

Who might be able to join this trial: - People who have cervical cancer that has come back or spread to other parts of the body, and whose cancer continued to grow or spread during or after chemotherapy - People whose treating doctor has decided that the drug Tivdak is an appropriate treatment option for them based on...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06953076 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 May 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are pre-menopausal (still having menstrual periods, not yet reached menopause). - People who have been diagnosed via ultrasound with a non-cancerous growth in the muscle wall of the uterus. - People who are experiencing ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967740 · Nikola Janovska Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇿 CZ

Who might be able to join this trial: - The person must give their informed consent to participate in the study - A cervical biopsy must have shown a high-grade lesion - The person must be between 18 and 46 years old - The transformation zone of the cervix must be visible during a colposcopy (a close-up examination of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06968871 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

**Who might be able to join this trial:** - Women aged 25 or older **Who may not be able to join:** - People who are currently having their menstrual period - People who are pregnant - People who have difficulty understanding numbered pain rating scales - People who have an active cancer diagnosis — meaning cancer tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06979180 · Papillex Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - Women between 25 and 55 years of age - Women who are not able to become pregnant — either because they have had a permanent sterilisation procedure (such as removal of the uterus or ovaries, or tubes being blocked) or have been through menopause for at least one year before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995833 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 June 2029
🇰🇷 KR

Who might be able to join this trial: - People whose condition meets the approved guidelines for this study drug as set out by Korean health authorities. - People who have signed and dated a consent form agreeing to take part (or whose legal representative has done so on their behalf). Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06998394 · Xiangbo Wan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and voluntarily agree to participate by signing a consent form before any study procedures begin. - Female participants aged 18 or older at the time of signing the consent form. - People whose general physical functioning is rated as 0 or 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07003620 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2028
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with locally advanced cervical cancer at a specific stage (FIGO stages IB3 to IIB) with a primary tumour larger than 4 cm. - People whose cervical cancer has been confirmed through a tissue sample (biopsy) as one of three specific types: squamous cell carcinoma,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07011836 · ISA Associates, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - You identify as a Black or African American woman - You have not had a Pap smear in the past 3 years, or have not had an HPV test in the past 5 years - You are between 21 and 65 years old - You are not currently pregnant - You have not had a surgery to remove your uterus (hystere...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07022470 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cervical cancer (confirmed by a tissue sample/biopsy) and your treatment plan includes a type of internal radiation therapy called brachytherapy. - You are generally able to carry out daily activities with little to no limitation (your doctor has rate...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07025213 · National Institute of Cancerología Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇲🇽 MX

Who might be able to join this trial: - People who are able to understand what the study involves and are willing to sign a consent form. - Women aged between 18 and 64 years old. - People who are available to attend exercise sessions as part of the study. - People who are willing and able to attend scheduled appointme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07027046 · National Cancer Institute, Naples Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with endometrial carcinoma (a type of uterine cancer, including a form called uterine carcinosarcoma), confirmed through laboratory testing of tissue - People who are generally well enough to carry out l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07041606 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇷🇺 RU

**Who might be able to join this trial:** - People who are female and aged 18 years or older - People who have given written consent to take part, including agreement for stored tumor tissue samples to be tested - People who have been newly diagnosed with advanced endometrial cancer (stage III or IV), confirmed by tis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07044505 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are scheduled to have gynecologic (female reproductive system) surgery at Stanford Healthcare - You still have your uterus and cervix intact - You have at least one fallopian tube and ovary on the same side that are still intact - You are 18 years of age or older - You ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07046923 · Eli Lilly and Company Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2030
🇨🇳 CN🇫🇷 FR🇯🇵 JP🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of the following advanced or spreading cancers: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), endometrial cancer, or triple negative breast cancer (a specific type of breast cancer that tests negative for certain r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07048327 · Wenwen Wang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 80 years old - People who need a hysteroscopy (a procedure to look inside the uterus) or a tissue scraping procedure to investigate or treat conditions inside the uterus, such as abnormal uterine lining growth, uterine polyps, fibroids inside the uterus...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07050745 · Kenyatta National Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
Kenya

"Who might be able to join this trial: - Women between the ages of 25 and 49 years old Who may not be able to join: - Women who are currently pregnant - Women who gave birth 6 weeks ago or less - Women who have already been diagnosed with cervical cancer Important: Always verify eligibility with the trial site direct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07051486 · Jiangsu HengRui Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments - Women aged 18 to 75 years old (inclusive) at the time of signing the consent form - People who have been diagnosed with cervical cancer, c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07054567 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and sign a consent form - People aged 18 to 75 years old - People whose doctors expect them to live for at least 3 more months - People who are generally able to care for themselves and carry out light activity (a standard measure o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07055399 · Fujian Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 70 years old - People who have signed a written agreement to take part in the study - People whose heart, liver, kidneys, and other major organs are working well enough, and who are generally well enough to carry out light activity or normal daily tasks (ECOG sc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07062016 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You are planning to have, or have already had, a full surgical staging procedure at Mayo Clinic, which includes removal of the uterus, both ovaries and fallopian tubes, and an assessment of the lymph nodes - Before surgery, your biopsy showe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07065552 · UNC Lineberger Comprehensive Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of uterine cancer called endometrioid histology cancer and are scheduled to have a hysterectomy (surgical removal of the uterus) with staging (to determine how far the cancer has spread). - People who are willing and able to...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07072364 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with uterine fibroids - People who have a scheduled appointment to discuss fibroid management at an outpatient clinic connected to the Hospital of the University of Pennsylvania Who may not be able to join: - People who are younger than 18 or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07075731 · University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are able to understand, speak, read, and write in English - People who are able to give voluntary written consent to participate before any research activities take place - People who have already had a hysterectomy (surgical r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07077876 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇮🇹 IT

Who might be able to join this trial: - People who are female and aged 18 years or older. - People who have been diagnosed through a tissue test with either endometrial adenocarcinoma (a type of uterine cancer) or atypical endometrial hyperplasia (abnormal thickening of the uterine lining). - People who had a procedure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07078682 · Zenchi, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are female and between 20 and 45 years old - People with a body mass index (BMI) between 18.5 and 24.9 (a measure of body weight relative to height, considered a "normal" range) - People who have previously been told by a doctor that they have uterine fibroids (no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You fully understand what the study involves and are willing to sign a consent form agreeing to take part. - You are a woman between 18 and 75 years of age. - You are able to carry out daily activities mostly or fully on your own, with little or no limitation from your illnes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07081984 · Therorna Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form agreeing to take part in the study. - People who are willing to follow the study schedule, including all visits and treatment plans. - People who have or have had a solid tumour that tested positive for a virus called HPV16. - Pe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07091032 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who speak English or Spanish - People with a body mass index (BMI) of 30 or higher (a measure of weight relative to height that falls in the "obese" category) - People aged 45–75 who are behind on bowel cancer screening — meaning their last stool test...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07092007 · Newish Technology (Beijing) Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** This trial has two groups (Cohort A and Cohort B). The criteria are listed separately for each. **Cohort A — People with HPV16-related precancerous cell changes (LSIL or HSIL):** - Women between 18 and 60 years of age - People who tested positive for the HPV16 strain during...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07092696 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Women between 18 and 75 years of age - People with locally advanced cervical cancer (of a specific cell type — squamous, adenocarcinoma, or adenosquamous) that has been confirmed by a tissue sample and has not yet been treated - People who have at least one tumour area of a m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07106359 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

**Who might be able to join this trial:** *For "Probands" (people who have already had genetic testing for Lynch syndrome):* - People who speak English - People who are at least 18 years old - People who have previously had genetic testing for Lynch syndrome - People who do not have a condition that would affect their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07107334 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have received a pathology diagnosis within the past 4 months of either low-grade (grade 1) uterine cancer of a specific type (endometrioid endometrial adenocarcinoma) or a pre-cancerous uterine condition called EIN (endometrial intraepith...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07108270 · GlaxoSmithKline Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus) that has come back or spread, confirmed by a laboratory test on a tissue sample - People whose cancer has a specific molecular feature — either "dMMR" or "MSI-H" — confirmed by the tr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114653 · Far Eastern Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - Women who have endometrial cancer (a type of uterine/womb cancer) and are considered at high risk of it coming back Who may not be able to join: - There are no stated exclusion criteria at this time (confirm with trial site) Important: Always verify eligibility with the trial s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116213 · Xiaorong Hou Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old. - People who are reasonably active and able to carry out daily activities, as measured by a standard health performance scale (ECOG score 0–2). - People who are expected to be able to follow the online adaptive radiotherapy treatment p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07120529 · Medical University of Silesia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇵🇱 PL

**Who might be able to join this trial:** - Women who had a specific type of major surgery to remove the cervix and surrounding tissue (called a radical hysterectomy, classified as type B or C) for early-stage cervical cancer - People whose cancer was at an early stage at the time of diagnosis (known as FIGO stages IB1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07121543 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with cervical cancer through a tissue or pathology test - People whose treatment plan includes a type of internal radiation therapy called brachytherapy for cervical cancer Who may not be able to join: - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07130240 · Obstetrics & Gynecology Hospital of Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2028
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with cervical cancer at a specific stage (FIGO 2018 stages IB2 or IIA2, with a tumour between 2 and 4 cm, confirmed by MRI scan) - People whose cervical cancer has been confirmed by tissue testing to be one of three types: squamous cell carcinoma, adenocarcinoma,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07139977 · William Bradley Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older who have been diagnosed with endometrial cancer (specifically endometrioid or serous types) that has come back or continued to grow, regardless of what stage it was when first diagnosed - People who have already had surgery to remove the uterus (hyster...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07146659 · Centre Hospitalier Intercommunal Creteil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇫🇷 FR

Who might be able to join this trial: - Women who are 18 years of age or older - People who are scheduled to have a surgical procedure called operative hysteroscopy (a procedure to examine and treat problems inside the uterus) - People who are able to give their agreement to take part in the study - People who speak Fr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07148154 · MiMARK Diagnostics, S.L. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇪🇸 ES

**Who might be able to join this trial:** - Women who have gone through menopause (at least 1 year without a period) and have abnormal uterine bleeding, where either the uterine lining measures more than 3mm on an internal ultrasound scan, OR the lining measures 3mm or less but the woman also has at least one of the f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180524 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇮🇹 IT

Who might be able to join this trial: - People who have uterine fibroids (non-cancerous growths in the womb) that are causing symptoms, with the fibroids located within or on the outer wall of the uterus and identified by ultrasound - People who already have a planned surgery scheduled to remove the uterus (hysterectom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07192068 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer (NSCLC), or sarcoma, confirmed by a laboratory test on a tissue or cell sample - People whose cancer has spread, cannot be surgically removed, and/or i...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07194551 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with Lynch syndrome, confirmed through genetic testing. - People who still have their uterus (have not had a hysterectomy). - People who are 30 years of age or older. Who may not be able to join: - People who have previously been diagnosed with end...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07198074 · National Cancer Institute (NCI) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with stage III or stage IVA endometrial cancer that can be measured on scans, stage IVB endometrial cancer (measurable or not), or endometrial cancer that has come back after previous treatment (measurable or not) - People whose cancer shows up as a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07202364 · MediLink Therapeutics (Suzhou) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the study and have voluntarily signed and dated a consent form before the study begins. - People aged 18 years or older at the time of signing the consent form. - People whose body weight falls within a healthy range, specifically a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07209449 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People whose general health and ability to carry out daily activities meets a specific standard (a score of 0 or 1 on a medical scale used to measure how cancer affects daily living — confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07209917 · University of California, Irvine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇮🇳 IN

Who might be able to join this trial: - You are a woman living with HIV, between 25 and 50 years old - You have been taking HIV medication (antiretroviral therapy) for more than 12 months and can show your medication card as proof - You have tested positive for high-risk HPV (a virus linked to cervical cancer) using a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07213609 · GlaxoSmithKline Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 28 September 2028
🇨🇦 CA🇯🇵 JP🇳🇱 NL🇪🇸 ES🇸🇪 SE🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by a tissue test (biopsy) to have an advanced solid tumour cancer that cannot be surgically removed, has spread to other parts of the body, or has come back after treatment - People whose tumour has been tested and found to have a specific gene...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07214584 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with a cervical cancer caused by HPV (Human Papillomavirus), specifically one of three types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cancer has been diagnosed at Stage I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07220239 · Jessica D. St. Laurent, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: **Pre-pilot study:** - People who are 18 years of age or older - People who are currently menstruating **Main study:** - People who carry a confirmed or likely harmful genetic change in one of these genes: MLH1, MSH2, MSH6, PMS2, or EPCAM (known as Lynch syndrome) - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07220512 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand the study and are willing to sign a consent form approved by an ethics board. - You are over 55 years old at the time of joining the study. - You have been newly diagnosed with a suspected cancer of the ovaries, the lining of the abdomen (peritoneum...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07224464 · New Phase Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Doctors expect you to live for at least 90 days. - You have been diagnosed (confirmed by a tissue sample/biopsy) with an advanced cancer that has spread, located somewhere between your upper chest and pelvis, and it has continued to grow after standard treatments and cannot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07232654 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇨🇳 CN

Who might be able to join this trial: - Women aged 18 to 75 years old at the time of signing the consent form - People who are well enough to carry out daily activities with little to no limitation (as measured by a standard medical scale called ECOG, with a score of 0 or 1) - People whose doctors expect them to live f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07233811 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇸🇪 SE

Who might be able to join this trial: - People who are scheduled to have a total robotic hysterectomy (removal of the uterus using robotic-assisted surgery), with or without removal of the ovaries or fallopian tubes, at one of the three participating hospitals - People having this surgery for either a non-cancerous (be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07248878 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 March 2026
🇮🇹 IT

Who might be able to join this trial: - You are a woman aged 18 or older - Your doctor suspects you may have cervical cancer and has recommended a biopsy as part of your normal care - You (or your legal representative or guardian) have given written consent to take part in the study and for your data to be used, before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07258186 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 September 2028
🇮🇹 IT

**Who might be able to join this trial:** - People who are older than 18 years of age - People who have been diagnosed through a tissue sample (biopsy or surgery) with a specific type of uterine cancer called endometrioid endometrial cancer, at any stage of the disease, including cases where the cancer has come back or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07263490 · Copenhagen University Hospital, Hvidovre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇩🇰 DK

**Who might be able to join this trial:** - You are over 18 years old - Your body mass index (a measure of body weight relative to height) is below 35 - You have had a normal vaginal swab test within the last three years - You may join whether or not you have previously been pregnant or given birth - You may join wheth...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07270666 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus) confirmed by laboratory testing - People whose cancer is at an advanced stage — specifically Stage III with some cancer remaining after surgery, or Stage IV (note: some Stage III pati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07275333 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇦 UA

Who might be able to join this trial: - Women between the ages of 30 and 60 - People who still have their uterus (have not had it surgically removed) - People whose situation meets local guidelines for cervical cancer screening - People who are willing and able to agree to take part in the study - People who are able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07276360 · Uganda Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 January 2028
Uganda

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with a specific type of cervical cancer (squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma) confirmed by a tissue test, and have not yet received any treatment for it - Your cancer has been staged u...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07278986 · Abramson Cancer Center at Penn Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus) - People who are scheduled to have surgery for endometrial cancer - People who are able to understand what the study involves and agree to fol...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07281430 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to give documented informed consent to participate - People who are 25 years of age or older - People who have a cervix that has not been removed or surgically altered - People who have been referred for a colposcopy procedure because recent cervic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07281599 · Qurasense Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 25 years old or older and still have their cervix. - People who have been referred for a colposcopy (a close-up examination of the cervix) following an abnormal Pap smear or HPV screening result. - People whose menstrual periods arrive on a regular cycle, rough...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07286188 · Northwestern University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People scheduled for a hysteroscopic myomectomy (a procedure to remove fibroids through the cervix) for uterine fibroids that have been confirmed by a pelvic ultrasound or MRI scan within the last 12 months - People aged 18 to 50 years old - People whose fibroids are between 1 an...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07290972 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇮🇳 IN

**Who might be able to join this trial:** - People who have been diagnosed with cervical cancer that has been confirmed through a tissue sample (biopsy) - People whose treatment plan includes radiation therapy — either as a main treatment, as a follow-up after surgery, or to help manage symptoms — with or without chemo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07292818 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 October 2027
🇺🇸 US

Who might be able to join this trial: - People who are willing to provide written agreement to take part in the study and allow their personal health information to be used. - People who are willing and able to follow the study procedures, as determined by the study doctor. - People who are 18 years of age or older at...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07298642 · National Taiwan University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2030
🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with cervical cancer (confirmed by a tissue sample/biopsy) that is at stage IIIC or higher. - You are between 20 and 85 years old. - You are fairly active and able to carry out daily activities with little to no limitation (confirm with trial site). -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07305727 · Centre Hospitalier Universitaire de Nīmes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇫🇷 FR

Who might be able to join this trial: - People who were treated for locally advanced cervical cancer (a specific range of stages) using a combination of radiation and chemotherapy as their main treatment, with no surgery involved. - People who have had at least 2 years of follow-up care after finishing their treatment....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07318324 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with endometrial cancer that has come back, and whose cancer has a specific type of gene change (called a RAS pathway mutation, which includes changes in genes such as KRAS, NRAS, HRAS, BRAF, MEK1, or MEK2), confirmed by a laboratory test on a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07318415 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a primary cancer of the uterine lining (endometrial carcinoma), including specific types such as endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07318727 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with endometrial cancer or a condition called atypical hyperplasia (an abnormal growth of cells in the lining of the uterus) - People who are undergoing fertility-preserving treatment (treatment that aims to protect t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07319429 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 45 years old - People who strongly wish to preserve their fertility (ability to have children) or to keep their uterus, even if they do not plan to have children - People newly diagnosed with endometrial cancer (cancer of the lining of the uterus), confirme...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07336134 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** *Phase I (clinic-based part of the trial):* - Women between the ages of 25 and 65 - People who already have a Pap smear appointment booked at Jefferson OBGYN Center City - People who are willing and able to give their agreement to take part in the study - People who agree to d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07340489 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily, have been fully informed about the study, and have signed a consent form - You are willing and able to follow all study procedures and attend all required visits - You are a woman between 18 and 75 years old - You are generally health...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07343531 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇪🇬 EG

Who might be able to join this trial: - People aged 18 years or older - People with early-stage cervical cancer (FIGO stage IB1) who are not suitable for surgery but can receive combined chemotherapy and radiation treatment - People with cervical cancer at FIGO stages IB2, IB3, IIA, or IIB - People with cervical cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07345897 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - Cisgender women, or transgender or non-binary people who have a cervix - People aged between 30 and 65 years old - People who are able to understand the trial and make their own decision about taking part Who may not be able to join: - People who have had a hysterectomy where th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07351110 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

Who might be able to join this trial: - You are 26 years old or older - You are a current patient at UF Internal Medicine and have had an appointment there in the last 2 months - You were assigned female sex at birth - You have been diagnosed with obesity or type 2 diabetes - You are not currently pregnant (based on se...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07368205 · University Hospital Hradec Kralove Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇨🇿 CZ

Who might be able to join this trial: - Women aged 18 or older who have been newly diagnosed with endometrial (uterine) cancer, regardless of the specific type - People who are having surgery as the main treatment for their cancer - People who had an expert ultrasound and/or CT scan before surgery (though the CT scan m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07372248 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - Women who are 18 years of age or older - Women who have been recommended to have a LLETZ procedure (a treatment to remove abnormal tissue from the cervix) based on an abnormal cervical smear test result and/or biopsy - People who are able to sign a written consent form agreei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07377734 · Wang Jianliu Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a specific type of uterine (womb) cancer called endometrioid adenocarcinoma (low-grade, G1 or G2) or a pre-cancerous condition called atypical endometrial hyperplasia. - People whose cancer or abnormal tissue, as confirmed by MRI or ultrasound,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07378098 · JW Pharmaceutical Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2028
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with uterine fibroids (non-cancerous growths in the uterus) Who may not be able to join: - People who experience irregular uterine bleeding or bleeding that is not related to ovulation - People who have previously had surgery to remove the entire u...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07380698 · Cukurova University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 August 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have cervical cancer, endometrial cancer, or vulvar cancer - People whose treatment plan involves a procedure called sentinel lymph node dissection (a technique to check nearby lymph nodes for cancer spread) - People whose procedure would use a dye called indocyanine g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07382583 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** **Women without a history of endometrial cancer or complex atypical hyperplasia ("unaffected women"):** - Women who are at least 18 years old - Women who can read and speak English or Spanish - Women who have not yet gone through menopause - Women who have no prior history of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383506 · Cogent Biosciences, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have an advanced solid tumour that has been confirmed by laboratory testing to carry a specific genetic change called a PIK3CA mutation, found in a blood and/or tumour sample. - People with PIK3CA-mutated endometrial (womb) cancer may be eligible for one group in...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07390864 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇪🇬 EG

**Who might be able to join this trial:** - Women aged 25 to 48 years - People with a body mass index (BMI) below 35 (a measure of weight relative to height) - People who have uterine fibroids (non-cancerous growths in the womb) causing symptoms such as heavy or abnormal bleeding, pelvic pain, or a feeling of pressure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07397624 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇮🇹 IT

Who might be able to join this trial: - Women who have been diagnosed with endometrial (uterine) cancer and are scheduled to have their uterus surgically removed with the goal of curing the cancer - People between the ages of 21 and 75 - People with a Body Mass Index (BMI) of 30 or higher (considered obese by standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07400809 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 June 2027
🇮🇳 IN

Who might be able to join this trial: - People who have cervical cancer that has spread to a small number of sites in the body (called oligo-metastatic) or come back in a small number of sites (called oligo-recurrent), whether or not radiation treatment has been used previously. - People whose cervical cancer had sprea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07400835 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 February 2028
🇩🇰 DK

Who might be able to join this trial: - People who have experienced vaginal bleeding after having no periods for at least 12 months, and who are currently being assessed for a possible uterine cancer diagnosis at a gynaecology department - People who are receiving care in the Central Denmark Region or the Southern Denm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07407647 · Ohio State University Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have anal, rectal, cervical, vaginal, or vulvar cancer and are receiving radiation treatment aimed at curing the cancer (either radiation alone, or radiation combined with internal radiation called brachytherapy) - People who are receiving or have previously recei...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07418749 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and sign a consent form - People who have been confirmed through a tissue or cell sample to have cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma) that is not suitable for major surge...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07424664 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You fully understand the study, agree to take part voluntarily, and are willing to sign a consent form. - You are a woman between 18 and 75 years old (inclusive). - Your doctor estimates you are expected to live for at least 3 months or more. - Your cancer has been confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07431788 · Erkan Gol Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - You are a woman aged 18 or older - You are scheduled to have your womb removed through an abdominal operation (called a total abdominal hysterectomy) for a non-cancer-related reason - You have been sexually active in the last 4 weeks - You are able to fill in a specific quest...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07435376 · Seoul National University Bundang Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with squamous cell carcinoma of the cervix (a specific type of cervical cancer), confirmed by laboratory testing of tissue. - People whose tumor is considered large, meaning it takes up a volume of 60 cc or more, or measures at least 6 cm across at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07435623 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 July 2025
🇮🇳 IN

Who might be able to join this trial: - You must be older than 18 years of age at the time of your diagnosis. - You must have been diagnosed with cervical cancer or endometrial (uterine) cancer, confirmed by a tissue sample test. - You must have received a specific type of radiation treatment (called IMRT) and/or inter...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07436793 · New Mexico Cancer Research Alliance Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of uterine cancer called endometrioid endometrial adenocarcinoma, confirmed by a biopsy or tissue sample taken within the past 8 weeks - People aged 18 or older - Women with this type of uterine cancer (any grade or stage)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07439497 · Samsung Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2026
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with cervical cancer confirmed by a laboratory tissue test, specifically one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - People whose cancer has been staged as FIGO stage IIB, III, or IVA (using the 2018 sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07444814 · Whitehawk Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a specific type of lung cancer called non-squamous EGFR-Wt non-small cell lung cancer (a form of lung cancer where a particular gene marker, EGFR, is not mutated — confirm with trial site) - People who have endometrial carcinoma (a cancer of the lining of the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07447895 · University of Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 April 2029
🇺🇸 US

Who might be able to join this trial: - People who are female - People who are 18 years of age or older - People who have been diagnosed with invasive cervical cancer and whose medical team has planned a course of treatment combining chemotherapy and radiation (chemoradiation) as their main treatment - People whose tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07453459 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 25 and 65 years old - People who still have their cervix (it has not been removed) - People who report that they have not had a cervical cancer screening in the last 3 years - People who own a smartphone - People who have internet access to use the Teal Health...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07454915 · PapiVax Biotech, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - Women between 18 and 60 years old who have been diagnosed with high-grade cervical cell changes (called CIN2 or CIN3), confirmed by a biopsy and reviewed by the trial's central team - People whose cervical swab sample tests positive for a specific strain of HPV called HPV16...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07458347 · Kestrel Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be willing and able to sign a consent form agreeing to take part in the trial. - You must have been diagnosed with a specific type of advanced cancer (such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, or ano...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07461818 · Basic Health International, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
El Salvador

Who might be able to join this trial: - Women between the ages of 30 and 49 years old - People who are not currently pregnant, confirmed by a urine pregnancy test - People whose HPV-positive status is recorded in Ministry of Health records - People who are willing to have a colposcopy (a close examination of the cervix...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07467772 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with one of these types of uterine cancer, confirmed by laboratory testing of tissue: uterine leiomyosarcoma (uLMS), endometrial stromal sarcoma (ESS), uterine adenosarcoma, or uterine PEComa. - People whose tumour tissue shows a moderate to strong...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07472153 · N.N. Alexandrov National Cancer Centre Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2030
Belarus

Who might be able to join this trial: - People aged 18 to 75 years old. - People who have a confirmed diagnosis of cervical cancer, proven through laboratory testing of tissue samples. - People whose cervical cancer falls into one of these three categories: cancer that has spread to distant parts of the body (stage IVB...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07480902 · Timser SAPI de CV Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇲🇽 MX

**Who might be able to join this trial:** - People who are in good general health - People aged between 18 and 85 years old - People who have fasted for at least 6 hours but no more than 12 hours before the study - People who have not had sexual intercourse in the 24 hours before the study - People who are willing to s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07493928 · General University Hospital, Prague Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇨🇿 CZ

Who might be able to join this trial: - People with cervical cancer who are planned to receive radiation therapy as their main treatment - People with a cancer stage classified as FIGO IB through IVA (a range of stages from early to locally advanced) - People who have signed a consent form agreeing to take part - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07526311 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 March 2027
🇪🇬 EG

**Who might be able to join this trial:** - Women between the ages of 25 and 48 years - People with a body mass index (a measure of body weight relative to height) below 35 - People who have uterine fibroids (non-cancerous growths in the womb) that are causing symptoms and have been recommended for surgery - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07527143 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 June 2027
🇺🇸 US

Who might be able to join this trial: - People who self-identify as Black and are 45 years of age or older with a uterus still present - People who were assigned female sex at birth - People who have experienced abnormal uterine bleeding or post-menopausal bleeding — this includes vaginal bleeding between periods, heav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07544680 · Exact Sciences Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 April 2028
🇺🇸 US

**Who might be able to join this trial:** **Group 1 (people being investigated for a possible uterine condition):** - People aged 45 or older, or people aged 18 or older who have at least one known risk factor for uterine cancer - People who have been diagnosed with abnormal uterine bleeding - People who are already s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07546825 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with uterine (endometrial) cancer, confirmed through a tissue sample taken from the uterine lining or a procedure to examine the inside of the uterus. - People whose cancer type and stage means that removal of lymph nodes in the pelvis may be recomm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07558889 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus), at any stage (I through IV) and any grade or type - People aged 18 years or older - People who have been assessed as fit enough for surgery using a standard medical scoring system called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07594015 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2031
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with recurrent endometrial cancer (a type of uterine cancer that has come back), confirmed by laboratory testing of tissue, including specific subtypes such as serous, endometrioid, carcinosarcoma, or clear cell. - People whose cancer has been teste...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07595224 · Siriraj Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇭 TH

**Who might be able to join this trial:** - You have been diagnosed with cervical cancer or cancer of the uterus (either uterine carcinoma or carcinosarcoma), confirmed by a tissue test. - You have had a hysterectomy (removal of the uterus, by any surgical method) for cervical or uterine cancer within the last 49 days...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07597083 · Beni-Suef University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇪🇬 EG

**Who might be able to join this trial:** - Women between the ages of 30 and 60 - People who have been diagnosed with cervical cancer (at any stage) and have finished their main cancer treatment - People who completed pelvic radiation therapy (which may have included external beam radiation and/or internal radiation c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07622901 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2028
🇺🇸 US

**Who might be able to join this trial:** - Women aged 18 or older - People who are able to give their informed consent to participate - People who can read and understand English, Spanish, or Haitian Creole - People who have been diagnosed with Type 1 (low-grade) endometrial cancer at any stage, confirmed by a tissue...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07625943 · All India Institute of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2029
🇮🇳 IN

**Who might be able to join this trial:** - Women between 18 and 65 years of age - People with cervical cancer that has been confirmed through laboratory testing of tissue samples - People whose cervical cancer has been staged by doctors as FIGO stage IB3, II, IIIB, or IIIC1 (these are specific medical classifications...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07631572 · Denise Fabian Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2029
🇺🇸 US

Who might be able to join this trial: - People who have been confirmed by laboratory testing to have a vaginal recurrence of endometrial cancer (specific types: endometrioid adenocarcinoma, uterine serous, carcinosarcoma, or clear cell) or cervical cancer (specific types: squamous, adenosquamous, or adenocarcinoma). -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07643012 · Rutgers, The State University of New Jersey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of uterine (endometrial) cancer, confirmed by laboratory testing of tissue, including certain subtypes such as endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated - People whose cancer has features that me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07645625 · University Medical Center Groningen Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2030
🇳🇱 NL

Who might be able to join this trial: **For the main observation group:** - You have cervical cancer that has come back, spread to other parts of the body, or keeps returning, and you are currently being treated or about to start treatment with a drug called pembrolizumab (either alone or combined with other medicines...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07646301 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years - People who have been diagnosed with cervical cancer (confirmed by a tissue or cell sample) at a specific stage of disease — FIGO stage IB3 or IIA2 - People whose scans show that the lymph nodes in the pelvis and near the main abdominal a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07647198 · Sheikh Shakhbout Medical City Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 August 2029
🇦🇪 AE

**Who might be able to join this trial:** - People who have voluntarily signed and dated a consent form before any screening procedures begin. - Premenopausal women aged 18 or older at the time of signing the consent form. - People who have a confirmed diagnosis of uterine fibroids, shown by a pelvic ultrasound done d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07653503 · University Medical Center Groningen Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇳🇱 NL

Who might be able to join this trial: - Women who are at least 18 years old, have their uterus and cervix still in place, and have been diagnosed with cervical cancer (confirmed by tissue testing) at an early stage (less than FIGO stage IB3) that is planned to be treated with standard surgery - People who are not pregn...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07690540 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with advanced or returning endometrial carcinoma or carcinosarcoma (specific types of uterine cancer), confirmed through laboratory testing of tissue - People who have not previously been treated with a type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07702799 · Mahmut Yassa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2028
Turkey (Türkiye)

Who might be able to join this trial: - Women between the ages of 18 and 90 years old. - People who have been scheduled for planned (non-emergency) keyhole surgery for endometrial (uterine) cancer. - People who are willing and able to sign a written consent form agreeing to take part. Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07702838 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇨🇳 CN

Who might be able to join this trial: - Women aged 18 or older at the time of signing the consent form - People with a confirmed diagnosis of cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, confirmed through tissue testing) - People whose cervical cancer is classified...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Endometrial Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Australian Gynaecological Cancer Foundation (AGCF) funds research across endometrial and other gynaecological cancers. Counterpart provides support and connection specifically for women with endometrial cancer.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.